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Antimicrobial resistance is a major global health concern with the worst consequences 
being increased disease severity, duration, morbidity, and mortality experienced by 
individuals in low-and middle-income countries, including Myanmar. Strains of 
Salmonella Typhi, the bacterium responsible of typhoid fever, which are resistant to most 
classes of antimicrobials are spreading in Southern Asia. However worldwide data on 
the emergence of antimicrobial resistance in Salmonella Typhi have scarcely been 
reviewed. Antimicrobial resistance has been shown to be higher in locations where 
inappropriate antimicrobial use is common in both community and hospital settings. Little 
is known about the common sources of antimicrobials in the community or antimicrobial 
consumption in hospital settings in Myanmar. Consequently, it is clear that more 
comprehensive data on the prevalence of antimicrobial resistant bacteria worldwide, and 
on antimicrobial consumption in both the community and hospitals settings are required 
to combat the challenges posed by increasing antimicrobial resistance.  
 
In this thesis I present three projects which have objectives relating to antimicrobial use 
and antimicrobial resistance. First, I present a systematic review of the prevalence of 
antimicrobial resistant Salmonella Typhi worldwide. These data will contribute evidence 
to country-level decisions on whether or not to introduce the typhoid conjugate vaccine. 
Second, I present an analysis of a healthcare utilisation survey conducted in Myanmar 
to investigate where individuals with fever sought healthcare, the determinants of 
seeking healthcare at a formal healthcare provider, the medicines that were used by 
individuals with fever, and which healthcare providers were the major sources of 
antibacterial medicines used by individuals with fever. Finally, I present a point-
prevalence survey of antimicrobial consumption and resistance at Yangon Children’s 
Hospital, Yangon, Myanmar. This point-prevalence survey was conducted to describe 
current antimicrobial prescribing practices and to identify targets for a pending 
antimicrobial stewardship programme. 
 
The work presented in this thesis and subsequent research outputs will contribute to an 
updated understanding of the prevalence of antimicrobial resistant Salmonella Typhi 
worldwide; help policy makers to understand major community sources of antimicrobials 
in Yangon Region, Myanmar; and give a snapshot of antimicrobial consumption and 
resistance at the largest referral children’s hospital in Myanmar and provide data on 
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1. Chapter 1  
A systematic review of the prevalence 
and distribution of antimicrobial resistant 




Typhoid fever (typhoid) is a systemic infection caused by the bacterium Salmonella 
enterica subspecies enterica serovar Typhi (Salmonella Typhi). It is an important cause 
of both illness and death in many low- and middle-income countries (LMICs) (1). The 
Institute for Health Metrics and Evaluation Global Burden of Disease Study estimated 
that in 2017 there were 10.9 million illnesses and 116.8 thousand deaths caused by 
typhoid worldwide (2,3). When stratified by United Nations (UN) geographical sub-
regions, 68.0% of global typhoid illnesses and deaths occurred in Southern Asia, and 
cumulatively 96.0% of typhoid illnesses and deaths occurred in only five UN sub-regions: 
Southern Asia, South-eastern Asia, Eastern Asia, Western Africa, and Eastern Africa 
(4).  
 
Transmission of Salmonella Typhi is associated with poor sanitation, and usually occurs 
following the consumption of food or water contaminated by the faeces of persons 
shedding Salmonella Typhi during acute infection, convalescence, or chronic carriage 
(5). Individuals who have limited access to microbiologically safe water, inadequate 
sewerage infrastructure, and who experience overcrowding have been shown to be at 
greatest risk of typhoid infection (6,7). Previous studies have indicated that children are 
most at risk of developing typhoid (8,9). A study reporting population-based surveillance 
data from five LMICs in Asia reported that 75.0% of blood culture-confirmed typhoid 
illnesses occurred in children ≤15 years of age despite that age group comprising only 
39.0% of the population under surveillance (9).  
 
The onset of symptoms following infection with Salmonella Typhi is often gradual and 
lacks a specific clinical presentation, making the clinical diagnosis of typhoid difficult. 
Infected individuals usually experience fever, and may have muscle weakness, 
headaches, abdominal discomfort, constipation and less commonly diarrhoea, nausea, 
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a dry cough, and a sore throat (5). A definitive diagnosis of typhoid requires the isolation 
of Salmonella Typhi from a normally sterile site, usually blood or bone marrow (10).  
 
However, in many LMICs where typhoid is endemic, blood or bone marrow culture is not 
routinely available, and diagnosis is often based on stool or urine culture, serological 
diagnostic tests such as the Widal test, or clinical suspicion (1,10). Since typhoid is just 
one of many febrile illnesses lacking specific symptoms, the absence of an easy to use 
and accurate rapid diagnostic test for typhoid increases the likelihood of misdiagnosis 
and inappropriate or delayed treatment.  
 
Another challenge for the effective management of Salmonella Typhi is increasing 
antimicrobial resistance (AMR). AMR is defined, from a microbiologic perspective, as 
the ability of a microorganism to survive exposure to an antimicrobial that would 
previously have killed it or stopped its growth (11). The presence of AMR can cause 
substantial delays to appropriate treatment being initiated and is correlated with infected 
individuals experiencing worse clinical outcomes (1,10,12). Consequently, antimicrobial 
susceptibility testing of Salmonella Typhi isolates is required to make well informed 
treatment decisions and to improve patient outcomes (13).  
 
Most antimicrobial susceptibility testing methods generate quantitative results (e.g., 
minimum inhibitory concentration [MIC] and inhibitory zone sizes). Based on these 
results, isolates are then classified as susceptible, intermediately susceptible, or 
resistant, with each classification correlated with the probability of treatment success 
using standardised interpretive criteria (13,14). In aggregate, antimicrobial susceptibility 
testing results can be useful for identifying the emergence of a new pattern of AMR 
among locally circulating pathogens, and for informing empiric treatment decisions (14). 
Patient-specific antimicrobial susceptibility testing results can also be used to refine 
individual treatment decisions (14). 
 
AMR is not a new phenomenon and has impacted the treatment of typhoid for more than 
50 years. Historically, chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole 
were the first-line antimicrobial treatments for typhoid (15). Chloramphenicol was 
discovered to be an effective treatment for typhoid by Woodward and colleagues in 
1948, and was subsequently introduced as the first antimicrobial treatment for typhoid 
(16). Reports of chloramphenicol-resistant Salmonella Typhi were documented by 1950 
(17) and the increasing prevalence of chloramphenicol resistance led to the adoption of 
alternative antimicrobials, such as ampicillin and trimethoprim-sulfamethoxazole, 
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through the 1960s and 1970s (18). With widespread use, multiple-drug resistant (MDR) 
Salmonella Typhi, defined as resistance to ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole (15), emerged. The first major outbreaks of MDR 
Salmonella Typhi occurred in Mexico and India in 1972 (19,20).  
 
Increasing reports of MDR Salmonella Typhi, particularly in Southern Asia, led to the 
widespread adoption of the quinolone nalidixic acid and fluoroquinolones such as 
ciprofloxacin and ofloxacin, from the early 1980s (21,22). After some years of 
widespread use of these antimicrobials, resistance to nalidixic acid was observed. Point 
mutations in the quinolone resistance determining region of the Salmonella Typhi 
genome are an important mechanism for both nalidixic acid and fluoroquinolone 
resistance, consequently resistance to nalidixic acid has long been used as an indicator 
of intermediate susceptibility to fluoroquinolones (23). Salmonella Typhi intermediately 
susceptible and resistant to nalidixic acid and fluoroquinolones were first isolated in 
Vietnam in the early 1990s before spreading more widely in Southern and South-eastern 
Asia (21,22). In a 2012 study from Pakistan, more than 90.0% of the Salmonella Typhi 
isolates were intermediately susceptible or resistant to ciprofloxacin (24). 
 
Resistance to nalidixic acid and fluoroquinolones is associated with treatment failure and 
prolonged fever (25). This necessitated the switch to extended-spectrum 
cephalosporins, such as ceftriaxone and cefotaxime, for locations with Salmonella Typhi 
that were MDR and resistant to fluoroquinolones (26). In 2016, an outbreak of 
extensively drug resistant (XDR) Salmonella Typhi, defined as resistance to first-line 
antimicrobials, a fluoroquinolone, and a cephalosporin, was reported initially in Sindh 
province, Pakistan (27). Since 2016, there have been more than 15,700 infections with 
XDR Salmonella Typhi in Pakistan (28) and travel-associated illnesses have been 
reported in Australia (29), Canada (30), Denmark (31), and the United States (32). 
Individuals infected with XDR typhoid have been successfully treated with the azalide 
azithromycin, and the carbapenem meropenem (15). 
 
The emergence of resistance in Salmonella Typhi to a succession of antimicrobials, and 
the emergence of XDR Salmonella Typhi, highlights the possibility of typhoid soon being 
untreatable with currently available antimicrobials. This underscores the urgency of 
typhoid control measures to reduce the global burden of typhoid (15). A key component 
for controlling typhoid is improving sanitation and increasing access to safe water (6,7). 
However, improvements in sanitation are associated with socioeconomic progress that 
has been slow in many countries where typhoid is endemic (33–35). Therefore, 
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antimicrobial stewardship (AMS) and typhoid vaccines will be important tools to contain 
the selection and spread of AMR typhoid. 
 
Vaccines have enormous potential to reduce typhoid incidence in endemic countries and 
to control typhoid outbreaks. However, historically typhoid vaccines have been mostly 
used by travellers from high-income countries (HICs) to typhoid endemic areas (36,37). 
Two typhoid vaccines, a live attenuated oral vaccine (Ty21a) and an injectable 
unconjugated polysaccharide vaccine using the purified Salmonella Typhi Vi antigen 
(ViPS), have been available since 1989 and 1994, respectively (38). The oral Ty21a 
vaccine can be safely given to individuals ≥6 years of age and has been shown to 
provide protection against typhoid for up to 5–7 years post-vaccination (33,39). In 
contrast, the injectable ViPS vaccine is only immunogenic in individuals ≥2 years of age. 
However, ViPS provides protection against typhoid for no more than three years, 
requiring regular revaccination (39). A 2008 World Health Organization (WHO) typhoid 
vaccine position paper recommended that typhoid endemic countries use either vaccine 
to reduce typhoid incidence and to control typhoid outbreaks (40). Few countries, 
however, implemented this recommendation (37). 
 
In 2017, a third typhoid vaccine, an injectable vaccine using the Salmonella Typhi Vi 
antigen conjugated to tetanus toxoid protein (TCV), was recommended for inclusion in 
routine immunisation programmes by the WHO Strategic Advisory Group of Experts 
(SAGE) Working Group on Typhoid Vaccines (41). TCV has been demonstrated to be 
immunogenic in individuals ≥6 months of age, and data show anti-Vi antibody 
persistence to 3-5 years post-vaccination (42). Consequently, a 2018 WHO typhoid 
vaccine position paper recommended that countries where typhoid is endemic, or where 
AMR typhoid has been reported, introduce TCV for individuals from 6 months of age 
(38). This is the first time that a vaccine has been recommended by WHO on the basis 
of containing the spread of AMR (38). 
 
1.1.2 Objective 
To assist countries with decision making about TCV introduction and other control 
efforts, we performed a systematic review of the published peer-reviewed literature to 
describe the prevalence and trends of AMR Salmonella Typhi isolates. Search terms 
were chosen to capture all published peer-reviewed scientific journal articles reporting 
antimicrobial susceptibility testing results on Salmonella Typhi isolates from normally 
sterile human specimens. As many papers presenting data on AMR Salmonella Typhi 
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also provided AMR data on isolates of select non-typhoidal Salmonella serovars, we 
also abstracted and described AMR data presented for these isolates. 
 
1.2 Methods 
1.2.1 Protocol registration 
Dr Marchello developed the draft protocol for the systematic review with critical input 
from me and Professor Crump. Following critical input, we uploaded the final protocol to 
the International Prospective Register of Systematic Reviews (PROSPERO) database 
(registration number: CRD4201913103) (43). Our review was completed in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement and guidelines (44) and was exempt from institutional ethics 
review. 
 
1.2.2 Development of search strategy 
Dr Marchello developed the search strategy with critical input from me and Professor 
Crump. The aim of the database search was to identify any peer-reviewed journal 
articles reporting the proportion (resistant/total tested) of Salmonella Typhi isolates 
collected from normally sterile specimens (e.g., blood or bone marrow) that were 
susceptible, intermediately susceptible, or resistant to a predefined list of antimicrobials 
(Table 1.1). The predefined list was informed by a table of suggested antimicrobial 
agents for Enterobacteriaceae groups A and B in the Clinical and Laboratory Standards 
Institute’s (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 29th 
edition (11) and discussions between Dr Marchello and Professor Crump. To ensure 
maximum breadth of results, no restrictions were applied with regard to location or dates 





Table 1.1 List of antimicrobials on which susceptibility data were abstracted, a 
systematic review of the prevalence and distribution of antimicrobial resistant 
Salmonella Typhi worldwide, 1972-2018 




β-Lactam/β-Lactam inhibitor combination agents Amoxicillin-clavulanic acid 
Folate pathway antagonists Trimethoprim-sulfamethoxazole 





Azalides  Azithromycin 
Carbapenems Meropenem 
Tetracylines Tetracycline 
Aminoglycosides a Gentamicin 
Antimicrobials are ordered chronologically by year of introduction. a Aminoglycosides 
such as gentamicin may appear active against Salmonella spp. in vitro but are not 
effective clinically and should not be reported as susceptible or used therapeutically for 
Salmonella Typhi (13). 
 
1.2.3 Literature searches 
Database search 
Dr Marchello systematically searched two major scientific databases, PubMed and Web 
of Science, for abstracts and titles relating to Salmonella Typhi and antimicrobial 
susceptibility and resistance on 16 April 2019 and 17 April 2019, respectively. The 
search parameters used to search each database are outlined in Table 1.2 and Table 
1.3.  
 
Table 1.2. PubMed search parameters, a systematic review of the prevalence and 
distribution of antimicrobial resistant Salmonella Typhi worldwide, 16 April 2019 
(Typhi OR typhoid OR “enteric 
fever”) 
AND 
(antimicrob* OR sensitiv* OR 
suscept* OR resist* OR emperic*) 
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Table 1.3. Web of Science search parameters, a systematic review of the 
prevalence and distribution of antimicrobial resistant Salmonella Typhi 
worldwide, 17 April 2019 
#4 #2 AND #1 
Refined by [excluding] DOCUMENT TYPES: (LETTER OR PATENT OR 
BIOGRAPHY OR ABSTRACT OR BOOK OR NEWS OR MEETING OR 
EDITORIAL) AND [excluding] RESEARCH AREAS: (SOCIOLOGY OR 
ENGINEERING OR PHYSICS OR CRYSTALLOGRAPHY OR GOVERNMENT 
LAW OR HISTORY OR SOCIAL SCIENCES OTHER TOPICS OR PLANT 
SCIENCES OR PSYCHOLOGY OR PUBLIC ADMINISTRATION OR 
MATHEMATICS OR SOCIAL ISSUES OR ENERGY FUELS OR NUTRITION 
DIETETICS OR BEHAVIOURAL SCIENCES OR FISHERIES OR COMPUTER 
SCIENCE OR THERMODYNAMICS OR INTERNATIONAL RELATIONS) 
Databases= WOS, BCI, CCC, INSPEC, KJD, MEDLINE, RSCI, SCIELO, 
ZOOREC Timespan=All years Search Language=Auto 
#3 #1 AND #2 
Databases= WOS, BCI, CCC, INSPEC, KJD, MEDLINE, RSCI, SCIELO, 
ZOOREC Timespan=All years Search Language=Auto 
#2 TOPIC: (antimicrob*) OR TOPIC: (sensitiv*) OR TOPIC: (suscept*) OR TOPIC: 
(resistan*) OR TOPIC: (emperic*) 
Databases= WOS, BCI, CCC, INSPEC, KJD, MEDLINE, RSCI, SCIELO, 
ZOOREC Timespan=All years Search Language=Auto 
#1 TOPIC: (Typhi) OR TOPIC: (typhoid) or TOPIC: (“enteric fever”) 
Databases= WOS, BCI, CCC, INSPEC, KJD, MEDLINE, RSCI, SCIELO, 
ZOOREC Timespan=All years Search Language=Auto 
 
Two databases were systematically searched to increase the number and breadth of 
journal articles retrieved. Different databases draw from different sources, so even when 
a single database was expected to provide comprehensive coverage of the subject area, 
it was preferable to utilise multiple databases (45,46). The two databases used for our 
systematic review were selected on the basis of past experience, knowledge of 
database search terms, and confidence in each database having sufficient coverage of 
the relevant subject area. Both databases were available to investigators through the 
University of Otago Libraries. The search strategy was tested by Dr Marchello for its 
ability to detect articles known a priori to be relevant to the review. On this basis, we 
deemed the search strategy to be appropriate and agreed that searching PubMed and 
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Web of Science would yield near complete coverage of the subject area, without 
requiring the time consuming screening of more titles and abstracts that were likely to 
be irrelevant (45). 
 
Following the systematic search of each database, we compiled eligible titles and 
abstracts in Endnote X8 (Clarivate Analytics, Philadelphia, PA, USA). After duplicates 
were removed in Endnote X8, the titles and abstracts were imported to an online 




We searched the reference lists of one previous systematic review of the prevalence of 
community-acquired bloodstream infections among hospitalised patients (47), and two 
previous systematic reviews of antimicrobial susceptibility in Salmonella Typhi (48,49) 
for additional studies. 
 
1.2.4 Study selection 
All stages of study selection were completed by at least two of four investigators (Dr 
Marchello, Professor Crump, Dr Ariella Perry Dale, and me). Two investigators 
completed each of these stages to reduce the likelihood of mislabelling studies as 
excluded or included, ensure accurate data, and to minimise bias (50). Eligible journal 
articles provided data on the susceptibility or resistance of Salmonella Typhi isolates 
collected from normally sterile human specimens (e.g., blood, bone marrow, etc.). 
Details on the time and place of sample selection were required, including for travel-
associated isolates (43). 
 
Title and abstract screening 
The purpose of title and abstract screening was to identify and exclude irrelevant studies 
from the need for further in-depth review (51). Dr Marchello and I independently 
screened the titles and abstracts of 6,864 unique journal articles. We each screened all 
titles and abstracts using the systematic review software Rayyan, and applied the 
selection criteria for title and abstract screening (Table 1.4). Journal articles identified as 
meeting the selection criteria for title and abstract screening by either investigator were 
included for full-text screening.   
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Table 1.4. Selection criteria for title and abstract screening, a systematic review 
of the prevalence and distribution of antimicrobial resistant Salmonella Typhi 
worldwide, 1972-2018 
Inclusion criteria 
• Reports typhoid, fever, bacteraemia, or sepsis of human patients 
• Reports isolation of Salmonella Typhi from normally sterile human specimens 
• Reports antimicrobial susceptibility testing of Salmonella Typhi isolates 
Exclusion criteria 
• Conference abstracts 
• Literature or systematic reviews 
• Policy reports, editorials, or opinions 
• Animal studies 
• Novel antimicrobial development studies 
• Reports only antimicrobial resistant Salmonella Typhi 
• Reports only patients with diarrhoea or stool isolates  




Dr Marchello and I retrieved full-text journal articles using one of the following methods: 
• Automated search using the ‘Find Full Text’ function in Endnote X8. 
• Manually searching for journal articles using Google Search.TM 
• Manually searching for journal articles using the PubMed database. 
• Manually searching for journal articles using the catalogue of the University of 
Otago Libraries. 
• Requesting journal articles through placing an interloan request with the 
University of Otago Libraries. 
 
All retrieved full-text journal articles were saved to a secure shared Syncplicity Drive 
(Axway, Phoenix, AZ, USA) folder. 
 
Full-text screening 
We screened, in parallel, 624 full-text journal articles for inclusion. During screening, 
attempts were made to translate any journal articles in a foreign language using an 
online translation tool (e.g., Google TranslateTM) and study team member language 
expertise. Professor Crump is fluent in English, French, and Kiswahili. Dr Marchello and 
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I are fluent in English. Dr Chuen Yen Hong assisted us by translating journal articles 
written in Bahasa Malaysia and Mandarin text.  
 
Full-text journal articles were screened to determine whether they contained the location 
(country) of sample collection, the time (year) of sample collection and the proportion, 
or sufficient data to calculate the proportion, of Salmonella Typhi isolates resistant to at 
least one antimicrobial. Full-text journal articles were screened independently by 
investigators utilising the blinding feature of the systematic review software Rayyan. The 
investigators applied the selection criteria for full-text screening found in Table 1.5. 
 
Table 1.5. Selection criteria for full-text screening, a systematic review of the 
prevalence and distribution of antimicrobial resistant Salmonella Typhi 
worldwide, 1972-2018 
Inclusion criteria 
• Location of sample collection available 
• Time period in calendar years of data collection available 
• Reports number or proportion of Salmonella Typhi isolates susceptible or 
resistant to any antimicrobial 
Exclusion criteria 
• Full-text of article was unavailable  
• Total number of Salmonella Typhi isolates could not be determined 
• Total number or proportion of AMR Salmonella Typhi isolates could not be 
determined 
• Journal article does not explicitly describe the isolate source (e.g., blood 
culture, bone marrow) 
 
Agreement on journal article inclusion was sought by consensus between investigators. 
Any disagreements about journal article inclusion were resolved by discussion between 
two investigators, with the involvement of a third investigator if necessary. The authors 
of journal articles screened during the title and abstract, and full-text screening 
processes were not concealed during the screening of full-text journal articles. No 
attempts were made to contact authors of included journal articles.  
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1.2.5 Data abstraction 
Consistent with best practice, all stages of data abstraction were completed by at least 
two of four investigators (Dr Marchello, Professor Crump, Dr Ariella Perry Dale, and me) 
using a standard form (50). We abstracted study characteristics and antimicrobial 
susceptibility data in parallel. Data were abstracted in a shared Google Sheets 
spreadsheet (Google LLC, Mountain View, CA, USA).  
 
Study characteristics that were abstracted included first author, publication year, 
normally sterile specimen type, data collection period in calendar years, and country of 
specimen collection. When a study reported on isolates collected from multiple 
countries, we documented each country as a separate study site. Antimicrobial 
susceptibility data abstracted were type of quantitative antimicrobial susceptibility testing 
results generated (e.g., MIC and inhibitory zone sizes), antimicrobial susceptibility 
testing interpretive criteria used (e.g., CLSI), number of total isolates tested; and the 
number of Salmonella Typhi, Salmonella Paratyphi A, Salmonella Paratyphi B, 
Salmonella Paratyphi C, Salmonella Typhimurium, and Salmonella Enteritidis isolates 
that tested susceptible, intermediately susceptible, or resistant to the predefined list of 
antimicrobials shown above (Table 1.1). 
 
In addition to abstracting antimicrobial susceptibility testing results for individual 
antimicrobials AMR phenotypes, data were also abstracted on the MDR and XDR 
phenotypes. We classified any Salmonella isolates resistant to chloramphenicol, 
ampicillin, and trimethoprim-sulfamethoxazole as MDR (15), and any Salmonella 
isolates resistant to these first-line antimicrobials, a fluoroquinolone, and a 
cephalosporin as XDR  (27). Fluoroquinolones for which data were abstracted were 
ciprofloxacin or ofloxacin and extended-spectrum cephalosporins were ceftriaxone or 
cefotaxime. We subsequently classified study sites by UN region and sub-region 
according to the Statistics Division of the United Nations Secretariat’s M49 standard 
(52). 
 
1.2.6 Quality assessment 
We used the reporting of antimicrobial susceptibility testing methods and interpretive 
criteria as a measure of study quality. We identified whether each article reported the 
methods used to generate an antimicrobial susceptibility testing result, and which 
interpretive criteria were used. Reporting of antimicrobial susceptibility testing methods 
and interpretive criteria is a useful measure of study quality as it shows compliance with 
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standard reporting practices (53), and because such reporting allows for results to be 
understood in context, such that they can be evaluated meaningfully. 
 
1.2.7 Analysis 
Dr Marchello and I independently compiled data for Salmonella Typhi, Salmonella 
Paratyphi A, Salmonella Paratyphi B, Salmonella Paratyphi C, Salmonella Typhimurium, 
and Salmonella Enteritidis isolates that were resistant to the predefined list of 
antimicrobials. Isolates were grouped by country, UN sub-region, and UN region. For 
each antimicrobial tested, we divided the number of resistant isolates by the total 
number of isolates tested and multiplied the resulting fraction by 100 to produce the 
proportion (%) of resistant isolates. When the number of resistant isolates were not 
explicitly provided, but the number of susceptible isolates was, we assumed that the 
remaining isolates were resistant. Time series graphs using 5-year intervals to illustrate 
the emergence of resistance in Africa and Asia over time were produced in Microsoft 
Excel 2016 (Microsoft Corporation, Redmond, WA, USA). Intervals of five years were 
chosen for histograms to produce a detailed but more stable time series than if individual 
years were presented. We chose to present time series graphs rather than pooling our 
findings using a meta-analysis because we did not think that a pooled estimate of 
worldwide AMR prevalence would be meaningful for assisting countries with making 
decisions about whether or not to introduce TCV and other typhoid control efforts. We 
also did not think that pooling regional or country-level AMR prevalence data would be 
meaningful, as AMR prevalence varied across time and place, and data from individual 
countries were limited and spanned from 1972 through 2018. Given changes in AMR 
Salmonella Typhi over time, a pooled estimate would have failed to represent the true 
situation in any individual country at any single time period and would have failed 
emphasize key trends in the emergence of AMR typhoid.  
 
1.3 Results 
1.3.1 Study selection 
Our search of the PubMed and Web of Science databases yielded 3,949 and 6,724 
eligible articles, respectively. An additional 152 articles were identified and included from 
the reference lists of previous relevant systematic reviews: 115 from a review by Reddy 
et al (48); 27 from a review by Deen et al (49); and 10 articles from a review by Marchello 
et al (47). The resulting 10,825 articles were collated in an Endnote library, where 2,163 
articles were excluded as duplicates, and 1,615 articles were excluded as they lacked 
information on author, title, or abstract. The remaining 7,047 titles and abstracts were 
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included for screening and were uploaded to the systematic review software Rayyan. 
An additional 183 articles were identified and excluded as duplicates by Rayyan, 
resulting in 6,864 to be screened. 
 
Of the 6,864 titles and abstracts screened, 6,211 articles were identified and excluded 
as not relating to antimicrobial susceptibility testing of Salmonella isolates. We retrieved 
624 (8.9%) of the 653 full-text articles eligible for full-text review. Of these, we excluded 
382 articles during full-text review. The most common reasons for excluding articles 
were because we were unable to stratify those isolates from normally sterile site 
specimens from isolates from sites that are not normally sterile, the site of specimen 
collection was not specified, or isolates were from non-human specimens (207 articles); 
data was insufficiently detailed to abstract (143 articles); and year of sample collection 
was not provided (56 articles). Of the 241 articles included for data abstraction, we 
excluded a further 44 articles during the data abstraction process, leaving 198 articles 





Figure 1.1. PRISMA flow diagram of eligible article selection, a systematic review 
on antimicrobial resistance among Salmonella Typhi worldwide, 1972-2018 
a The sum of exclusion criteria for full-text articles (n=491) is greater than the number of 
excluded articles (n=382), as some studies met multiple exclusion criteria. 
b Articles which were unable to be translated using language expertise or translation 
resources are listed in Appendix 1.  
15 
 
1.3.2 Study characteristics 
The 198 articles included for analysis reported on 55,459, median 80 (range 2 to 5,191) 
per article, Salmonella Typhi isolates collected from 1972 through 2018. Isolates were 
collected in 38 countries from four UN regions and 12 UN sub-regions. Four (2.0%) 
articles reported data collection in multiple countries, resulting in a total of 216 study 
sites (Table 1.6). Of these, 159 (73.6%) were in Asia, 54 (25.0%) were in Africa, two 
(0.9%) were in the Americas, and one (0.5%) was in Europe. There were 127 (58.8%) 
study sites located in Southern Asia, including 74 (34.3%) in India, 24 (11.1%) in Nepal, 
and 20 (9.3%) in Pakistan. No articles reported data from Latin America and the 
Caribbean, Central America, Northern America, Eastern Europe, Northern Europe, 




Table 1.6. Number of study sites reporting data on antimicrobial susceptibility testing results by UN region, sub-region and country, a 
systematic review of the prevalence and distribution of antimicrobial resistant Salmonella Typhi worldwide, 1972-2018 
UN region, sub-region Country Number (%) of study sites References 
















































Table 1.6 (continued). 
Western Africa 
























Americas  2 (0.9) 
 
Central America  - 0 (0.0)  
Latin America and the Caribbean - 0 (0.0)  
Northern America - 0 (0.0)  
South America Peru 2 (0.9) (95,96) 
Asia  159 (73.6) 
 

















































































Table 1.6 (continued). 
Europe  1 (0.5) 
 
Eastern Europe - 0 (0.0)  
Northern Europe - 0 (0.0)  
Southern Europe Greece  1 (0.5) (248) 
Western Europe - 0 (0.0)  
Oceania  0 (0.0) 
 
Australia and New Zealand - 0 (0.0)  
Melanesia - 0 (0.0)  
Micronesia - 0 (0.0)  







The laboratory methods used, and quantitative antimicrobial susceptibility testing results 
generated, were reported in 189 (95.5%) of 198 articles. Quantitative antimicrobial 
susceptibility testing results could broadly be divided into two groups:  
1) MIC from agar dilution, Epsilometer-test (E-test), broth dilution, or various 
automated instruments; and  
2) zones of inhibition from disk diffusion.  
 
Among the 198 articles analysed, 102 (51.5%) reported the interpretation of disk 
diffusion only, 73 (36.9%) reported the interpretation of a combination of zones of 
inhibition and MIC, 14 (7.1%) reported the interpretation of MIC only, and nine (4.5%) 
did not report which antimicrobial susceptibility testing results were interpreted (Table 
1.7). 
 
Table 1.7. Number of articles reporting the methods used to generate quantitative 
antimicrobial susceptibility results, a systematic review of the prevalence and 
distribution of antimicrobial resistant Salmonella Typhi worldwide, 1972-2018 (N= 
198) 
Antimicrobial susceptibility testing methods 
Number (%) of 
articles 
Disk diffusion only 102 (51.5) 
Disk diffusion and MIC 73 (36.9) 
MIC only 14 (7.1) 
Not reported 9 (4.5) 
Disk diffusion only 102 (51.5) 
Disk diffusion and MIC 73 (36.9) 
 
Various interpretive criteria were used to interpret the antimicrobial susceptibility testing 
results and classify isolates as susceptible, intermediately susceptible, or resistant. The 
use of a specific antimicrobial susceptibility testing criteria was reported in 139 (70.2%) 
of 198 articles; 129 (65.2%) reported using Clinical and Laboratory Standards Institute 
(CLSI) interpretive criteria, 10 (5.1%) reported using European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), British Society for Antimicrobial 
Chemotherapy (BSAC), Antibiogram Committee of the French Society of Microbiology 
(CASFM), or a combination of interpretive criteria, and 59 (29.8%) did not report which 
criteria were used to interpret the antimicrobial susceptibility testing results (Table 1.8).  
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Table 1.8. Use of antimicrobial susceptibility testing interpretive criteria by 
articles reporting data on antimicrobial susceptibilities of Salmonella Typhi, a 
systematic review of the prevalence and distribution of antimicrobial resistant 
Salmonella Typhi worldwide, 1972-2018 (N= 198) 
Antimicrobial susceptibility testing interpretive criteria 
Number (%) of 
articles 
Clinical and Laboratory Standards Institute a 129 (65.2) 
European Committee on Antimicrobial Susceptibility 
Testing 
3 (1.5)  
British Society for Antimicrobial Chemotherapy 3 (1.5)  
Antibiogram Committee of the French Society of 
Microbiology 
2 (1.0) 
Combination b 2 (1.0) 
Not reported 59 (29.8) 
a Prior to 2005, CLSI was known as the National Committee for Clinical Laboratory 
Standards (NCCLS); b One article reported the use of a combination of BSAC and 
EUCAST interpretive criteria, and one article reported the use of combination of CLSI 
and EUCAST interpretive criteria. 
 
1.3.3 Antimicrobial resistance in Salmonella Typhi 
Antimicrobial resistance worldwide 
Of 55,459 Salmonella Typhi isolates tested for AMR, 9,056 (25.9%) of 34,996 were 
resistant to chloramphenicol, 13,481 (38.8%) of 34,783 to ampicillin, and 13,366 (37.9%) 
of 35,270 to trimethoprim-sulfamethoxazole (Table 1.9). Of isolates, 12,666 (35.5%) of 
35,659 were MDR, 9,495 (64.7%) of 14,671 were resistant to nalidixic acid, and 6,979 
(19.4%) and 5,406 (15.0%) of 35,975 were intermediately susceptible or resistant to 
ciprofloxacin, respectively. Of isolates, 918 (2.3%) of 40,887 were resistant to 
ceftriaxone and cefotaxime, 270 (4.5%) of 6,043 to azithromycin, 1435 (40.7%) to 
tetracycline, and 21 (2.5%) of 834 to meropenem. 
 
Worldwide, when stratified by five-year periods, resistance of Salmonella Typhi to 
chloramphenicol was first identified in the period 1972-1979 and prevalence peaked in 
the period 1990-1994 when 955 (77.0%) of 1,241 isolates were chloramphenicol-
resistant (Figure 1.2). Resistance of Salmonella Typhi to both ampicillin and 
trimethoprim-sulfamethoxazole were first identified in the period 1980-1984 and 
prevalence peaked in the period 1990-1994 when 793 (73.6%) of 1,077, and 871 
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(79.3%) of 1,098 isolates were ampicillin-resistant and trimethoprim-sulfamethoxazole-
resistant, respectively. MDR was first identified in the period 1990-1994 when 1,205 
(44.3%) of 2,719 isolates were resistant and prevalence peaked in the period 2010-2014 
when 5,981 (44.6%) of 13,416 isolates were resistant. 
 
Resistance of Salmonella Typhi to nalidixic acid, the fluoroquinolones ciprofloxacin and 
ofloxacin, and the extended-spectrum cephalosporins ceftriaxone and cefotaxime was 
first identified in the period 1990-1994. The prevalence of resistance to nalidixic acid 
was lowest in the period 1995-1999 when 85 (28.3%) of 300 isolates were resistant and 
prevalence peaked in the period 2015-2018 when 662 (85.6%) of 773 of isolates were 
resistant. Resistance to fluoroquinolones was lowest in the period 1990-1994 when 11 
(0.4%) of 3,023 isolates were resistant and prevalence peaked in the period 2010-2014 
when 6,220 (37.8%) of 16,472 isolates were resistant. Resistance to extended-spectrum 
cephalosporins was lowest in the period 2005-2009 when 35 (0.4%) of 9,630 isolates 
were resistant and prevalence peaked in the period 1995-1999, when 310 (8.0%) of 
3,853 isolates were resistant. 
 
Two studies from Pakistan (239,243) reported XDR isolates in the period 2015-2018; 14 
(2.6%) of 546 isolates were XDR. Resistance of Salmonella Typhi to azithromycin was 
first identified in the period 2005-2009, when 27 (2.1%) of 1,279 isolates were 
azithromycin-resistant. Resistance of Salmonella Typhi to meropenem was first 




Table 1.9. Antimicrobial susceptibilities of Salmonella Typhi isolates from 198 included articles worldwide, a systematic review of the 
prevalence and distribution of antimicrobial resistant Salmonella Typhi worldwide, 1972-2018 
 Total, N Susceptible, n 
Intermediately 




Individual drugs      
Chloramphenicol 34,996 25,907 33 9,056 (25.9) 
Ampicillin 34,783 21,197 105 13,481 (38.8) 
Amoxicillin 4,128 1,569 34 2,525 (61.2) 
Amoxicillin and clavulanic acid 1,288 1,184 1 103 (8.0) 
Trimethoprim-sulfamethoxazole 35,270 21,896 8 13,366 (37.9) 
Nalidixic acid 14,671 5,084 92 9,495 (64.7) 
Ciprofloxacin 35,975 23,590 6,979 5,406 (15.0) 
Ofloxacin 12,590 8,095 389 4,106 (32.6) 
Ceftriaxone 35,302 34,771 81 450 (1.3) 
Cefotaxime 5,585 5,072 45 468 (8.4) 
Azithromycin 6,043 5,759 14 270 (4.5) 
Meropenem 834 813 0 21 (2.5) 
Tetracycline 3,527 2,068 24 1,435 (40.7) 
Gentamicin 6,169 5,477 16 676 (11.0) 
Resistance phenotypes      
Multiple-drug resistant 35,659 0 0 12,666 (35. 5) 
Extensively drug resistant 546 0 0 14 (2.6) 
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Figure 1.2. Antimicrobial resistant Salmonella Typhi worldwide, a systematic review of the prevalence and distribution of antimicrobial 






Figure 1.2 (continued). 
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] represents the number of isolates resistant to the specified antimicrobial during the specified time period divided by the 
total number of isolates for which antimicrobial susceptibility testing was completed for that antimicrobial during that time period. Values in 
parenthesis represent the prevalence of resistance. a Antimicrobials ordered chronologically by year of introduction and grouped by colour 




Antimicrobial resistance in Asia 
In Asia, when stratified by five-year periods, resistance of Salmonella Typhi to 
chloramphenicol was first identified in the period 1972-1979 and prevalence peaked in 
the period 1990-1994 when 954 (80.6%) of 1,184 isolates were chloramphenicol-
resistant (Figure 1.3). Resistance of Salmonella Typhi to both ampicillin and 
trimethoprim-sulfamethoxazole was first identified in the period 1980-1984 and 
prevalence peaked in the period 1990-1994 when 793 (76.0%) of 1,044, and 859 
(82.5%) of 1,041 isolates were ampicillin-resistant and trimethoprim-sulfamethoxazole-
resistant, respectively. MDR Salmonella Typhi was first identified and prevalence 
peaked in the period 1990-1994 when 1,205 (44.3%) of 2,719 isolates were resistant. 
 
Resistance of Salmonella Typhi to nalidixic acid, the fluoroquinolones ciprofloxacin or 
ofloxacin, and the extended-spectrum cephalosporins ceftriaxone or cefotaxime, was 
first identified in the period 1990-1994. Resistance to nalidixic acid was observed in 316 
(49.1%) of 644 isolates in the period 1990-1994 and increased to 659 (86.8%) of 759 
isolates in the period 2015-2018. Resistance to fluoroquinolones was between 0.0% and 
8.0% until the period 2010-2014 when 6,164 (45.9%) of 13,458 isolates were resistant 
and the period 2015-2018 when 2,436 (37.0%) of 6,585 isolates were resistant. 
Resistance to extended-spectrum cephalosporins was first observed in the period 1990-
1994 when 18 (0.9%) of 2068 isolates were resistant and prevalence peaked in the 
period 1995-1999 when 275 (7.4%) of 3,734 isolates were resistant before falling to 
between 0.3% and 5.7% in subsequent time periods. 
 
XDR Salmonella Typhi was first identified in two studies from Pakistan in the period 
2015-2018; 14 (2.6%) of 546 isolates were XDR. Resistance of Salmonella Typhi to 
azithromycin was first identified in the period 2005-2009, when 27 (2.1%) of 1,279 
isolates were resistant. Resistance of Salmonella Typhi to meropenem was first 
identified in the period 2010-2014, when 1 (0.7%) of 136 isolates were meropenem-
resistant. Prevalence of resistance of Salmonella Typhi to meropenem peaked in the 
period 2015-2018 when 20 (3.4%) of 594 isolates were reported as meropenem-
resistant. Meropenem-resistant Salmonella Typhi isolates were only observed in Asia.
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Figure 1.3. Antimicrobial resistant Salmonella Typhi in Asia, a systematic review of the prevalence and distribution of antimicrobial 
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] represents the number of isolates resistant to the specified antimicrobial during the specified time period divided by the 
total number of isolates for which antimicrobial susceptibility testing was completed for that antimicrobial during that time period. Values in 
parenthesis represent the prevalence of resistance. a Antimicrobials ordered chronologically by year of introduction and grouped by colour 




Antimicrobial resistance in Africa 
Among studies from Africa, resistance of Salmonella Typhi to chloramphenicol, 
ampicillin, and trimethoprim-sulfamethoxazole was first identified in the periods 1972-
1979, 1980-1984, and 1990-1994, respectively (Figure 1.4). MDR Salmonella Typhi was 
first identified in the period 2000-2004. Of isolates during the periods 2000-2004, 2005-
2009, and 2010-2014, 28 (21.9%) of 128, 198 (21.2%) of 932, 2,132 (76.5%) of 2,787 
isolates were MDR, respectively. From 2015 through 2018, only one study reported 41 
(38.0%) of 108 isolates were MDR (77). 
 
Resistance of Salmonella Typhi to nalidixic acid was first observed in Africa in the period 
1995-1999 when 11 (15.7%) of 70 isolates were resistant. The prevalence of nalidixic-
acid resistant Salmonella Typhi isolates peaked in the period 2015-2018 when 3 (21.4%) 
of 14 isolates were resistant. Resistance of Salmonella Typhi to the fluoroquinolones 
ciprofloxacin or ofloxacin was first observed in the period 2000-2004 when 1 (0.3%) of 
286 isolates were resistant. The prevalence of fluoroquinolone-resistance peaked in the 
period 2015-2018 when 8 (3.7%) of 219 isolates were resistant. Resistance of 
Salmonella Typhi to the extended-spectrum cephalosporins ceftriaxone and cefotaxime 
was first observed, and prevalence peaked, in the period 1995-1999 when 35 (29.4%) 
of 119 isolates were resistant. In subsequent time periods the prevalence of extended-
spectrum cephalosporin resistant isolates has been consistently lower than observed in 
1995-1999. 
 
No reports of XDR Salmonella Typhi were observed in Africa. Five azithromycin-
resistant Salmonella Typhi isolates were observed: 3 (0.6%) of 484 isolates in the period 
2010-2018, and 2 (0.4%) of 470 isolates in the period 2010-2018. Seven isolates were 





Figure 1.4. Antimicrobial resistant Salmonella Typhi in Africa, a systematic review of the prevalence and distribution of antimicrobial 






Figure 1.4 (continued). 
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] represents the number of isolates resistant to the specified antimicrobial during the specified time period divided by the 
total number of isolates for which antimicrobial susceptibility testing was completed for that antimicrobial during that time period. Values in 
parenthesis represent the prevalence of resistance. a Antimicrobials ordered chronologically by year of introduction and grouped by colour 




1.3.4 Antimicrobial resistance in other typhoidal Salmonella  
Among 12,850 other typhoidal Salmonella isolates tested, 10,464 (81.4%) were 
Salmonella serovar Paratyphi A; 1,305 (10.2%) Salmonella Paratyphi A or Paratyphi B; 
1,012 (7.9%) unspecified Salmonella ‘Paratyphi,’ 68 (0.5%) Salmonella Paratyphi B, and 
one (<0.1%) Salmonella Paratyphi C. Antimicrobial susceptibility testing data for 
Salmonella Paratyphi A and Paratyphi B are presented in Table 1.10. One study from 
China in 2007 reported a single Salmonella Paratyphi C isolate; this isolate was resistant 
to nalidixic acid alone (98). 
 
Ten studies reported data on unspecified Salmonella ‘Paratyphi’ isolates, or combined 
data on Salmonella Paratyphi A and Salmonella Paratyphi B. Antimicrobial susceptibility 
testing data for these isolates were not abstracted as susceptibility results could not be 
reliably classified to serovar level.  
 
1.3.5 Antimicrobial resistance in non-typhoidal Salmonella 
Of 1,462 non-typhoidal Salmonella enterica isolates tested, 793 (54.2%) were 
Salmonella Typhimurium and 669 (45.8%) were Salmonella Enteritidis. Antimicrobial 
susceptibility testing data for typhoidal Salmonella other than serovar Typhi are 




Table 1.10. Antimicrobial susceptibilities of typhoidal Salmonella isolates other than serovar Typhi, a systematic review of the 
prevalence and distribution of antimicrobial resistant Salmonella Typhi worldwide, 1972–2018 
Serovar Total, N Susceptible, n 
Intermediately 




Salmonella Paratyphi A 
Individual drugs      
Chloramphenicol 7,809 6,897 1 911 (11.7) 
Ampicillin 6,081 4,869 0 1,212 (19.9) 
Amoxicillin 452 381 27 44 (9.7) 
Amoxicillin and clavulanic acid 105 102 0 3 (2.9) 
Trimethoprim-sulfamethoxazole 6,737 5,803 0 934 (13.9) 
Nalidixic acid 3,117 676 1 2,440 (78.3) 
Ciprofloxacin 4,079 2,231 54 1,794 (44.0) 
Ofloxacin 5,253 3,798 222 1,233 (23.5) 
Ceftriaxone 7,215 7,128 30 57 (0.8) 
Cefotaxime 733 685 6 42 (5.7) 
Azithromycin 2,184 2,139 0 45 (2.1) 
Meropenem 356 356 0 0 (0.0) 
Tetracycline 429 422 0 7 (1.6) 




Table 1.10 (continued). 
Resistance phenotypes      
Multiple-drug resistant 7,335 - - 650 (8.9) 
Extensively drug resistant 96 - - 0 (0.0) 
Salmonella Paratyphi B 
Individual drugs      
Chloramphenicol 67 0 1 68 (1.5) 
Ampicillin 43 0 23 66 (34.8) 
Amoxicillin 0 0 0 0 - 
Amoxicillin and clavulanic acid 0 0 0 0 - 
Trimethoprim-sulfamethoxazole 56 0 10 66 (15.2) 
Nalidixic acid 8 0 9 17 (52.9) 
Ciprofloxacin 49 0 0 49 (0.0) 
Ofloxacin 45 0 18 63 (28.6) 
Ceftriaxone 65 0 0 65 (0.0) 
Cefotaxime 52 0 0 52 (0.0) 
Azithromycin 49 0 0 49 (0.0) 
Meropenem 46 0 0 46 (0.0) 
Tetracycline 2 0 0 2 (0.0) 
Gentamicin 3 0 0 3 (0.0) 
Resistance phenotypes      
Multiple-drug resistant 50 - - 0 (0.0) 
Extensively drug resistant 46 - - 0 (0.0) 
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Table 1.11. Antimicrobial susceptibilities of non-typhoidal Salmonella isolates, a systematic review of the prevalence and distribution 
of antimicrobial resistant Salmonella Typhi worldwide, 1972–2018 
Serovar Total, N Susceptible, n 
Intermediately 





Individual drugs      
Chloramphenicol 775 336 0 439 (56.6) 
Ampicillin 753 62 0 691 (91.8) 
Amoxicillin 0 0 0 0 (0.0) 
Amoxicillin and clavulanic acid 29 5 0 24 (82.8) 
Trimethoprim-sulfamethoxazole 757 97 0 660 (87.2) 
Nalidixic acid 45 43 0 2 (4.4) 
Ciprofloxacin 25 25 0 0 (0.0) 
Ofloxacin 468 450 17 1 (0.2) 
Ceftriaxone 75 73 0 2 (2.7) 
Cefotaxime 109 108 0 1 (0.9) 
Azithromycin 445 396 0 49 (11.0) 
Meropenem 0 0 0 0 (0.0) 
Tetracycline 665 503 0 162 (24.4) 




Table 1.11 (continued). 
Resistance phenotypes      
Multiple-drug resistant 450 - - 408 (90.7) 
Extensively drug resistant 0 - - 0 (0.0) 
Salmonella Enteritidis 
Individual drugs      
Chloramphenicol 669 229 0 440 (65.8) 
Ampicillin 658 173 0 485 (73.7) 
Amoxicillin 0 0 0 0 (0.0) 
Amoxicillin and clavulanic acid 21 2 0 19 (90.5) 
Trimethoprim-sulfamethoxazole 664 287 0 377 (56.8) 
Nalidixic acid 66 60 0 6 (9.1) 
Ciprofloxacin 76 76 0 0 (0.0) 
Ofloxacin 461 437 23 1 (0.2) 
Ceftriaxone 131 130 0 1 (0.8) 
Cefotaxime 209 207 0 2 (1.0) 
Azithromycin 420 419 0 1 (0.2) 
Meropenem 0 0 0 0 (0.0) 
Tetracycline 501 193 0 308 (61.5) 
Gentamicin 579 573 0 6 (1.0) 
Resistance phenotypes      
Multiple-drug resistant 420 - - 339 (80.7) 




1.4.1 Key findings 
We described evidence of widespread AMR of Salmonella Typhi to a growing number 
of antimicrobial agents from several antimicrobial classes, the emergence of XDR 
Salmonella Typhi in Asia, and the expansion of MDR Salmonella Typhi in Africa. We 
also observed that the emergence of AMR Salmonella Typhi in Africa has occurred later 
than in Asia. In Africa, resistance to fluoroquinolones and extended-spectrum 
cephalosporins was also recently observed, although XDR Salmonella Typhi was not 
identified.  
 
Although we aimed to capture data from study sites worldwide, only three study sites 
located outside of the Asia and Africa regions met our inclusion criteria; two study sites 
from Peru (95,96) and one study site from Greece (248). Southern Asia, South-eastern 
Asia, Eastern Africa, and Western Africa were the most represented UN sub-regions in 
our review. Notably, no articles reported antimicrobial testing results from Oceania. Our 
results show variability in reporting of antimicrobial susceptibility testing results between 
UN regions, neighbouring countries, and even within individual countries over time. 
 
1.4.2 Observed emergence of key AMR phenotypes 
Other than ampicillin-resistant Salmonella Typhi in South Africa in 1980 (82), the first 
observation of every AMR phenotype examined in our review was from study sites in 
Asia. The first AMR phenotype identified in this review was resistance to 
chloramphenicol from a study from Vietnam in 1972 (117). Following this, we observed 
increasing prevalence of resistance to all traditional first-line antimicrobials in Asia 
through the 1980s. The first reports of chloramphenicol and ampicillin-resistance in the 
Africa region observed in this review were in South Africa in 1979 and 1980, respectively 
(82). The first observation of resistance to trimethoprim-sulfamethoxazole in Africa was 
in Kenya in 1994 (58). 
 
MDR typhoid was first observed in Southern Asia in the early 1990 
(126,133,157,184,237) and was followed by a substantial increase in prevalence 
throughout the decade. The first MDR Salmonella Typhi isolates in Africa were then 
observed in Malawi in 2001 (62). It has been suggested, based on whole genome 
sequencing studies, that MDR typhoid emerged in Eastern Africa following 
intercontinental transmission from South-eastern Asia, rather than through independent 
selection of the phenotype in the African region (249).  
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In response to increased prevalence of MDR, the fluoroquinolone ciprofloxacin became 
the preferred treatment for typhoid in place of the conventional first-line antimicrobials 
(250). Resistance to ciprofloxacin was first observed in Vietnam in the early 1990s, 
before being independently selected for throughout South and Southeast Asia (21,22). 
The first observation of ciprofloxacin-resistance in Africa was in Egypt in 2002 (81), and 
through to the most recent time period observed, the prevalence of ciprofloxacin-
resistant Salmonella Typhi has remained lower in Africa than in Asia. 
 
As fluoroquinolone resistant Salmonella Typhi became widespread, extended-spectrum 
cephalosporins and azithromycin are now the recommended treatments for typhoid in 
areas where circulating Salmonella Typhi strains are MDR and also resistant to 
fluoroquinolones (251). While the overall picture has been of ever widening AMR in 
Salmonella Typhi, it is possible that traditional first-line antimicrobials may regain 
effectiveness in settings where isolates are shown to be susceptible (252,253). 
 
Occasional reports of typhoid patients infected with ceftriaxone-resistant Salmonella 
Typhi have been published (152,239), but neither large outbreaks nor widespread 
endemic prevalence had been seen until the recent outbreak of XDR Salmonella Typhi 
in Pakistan (254). In this outbreak to date, the WHO has received reports of >5,000 
individuals infected with XDR Salmonella Typhi (255) and travel-related cases have 
been confirmed in several other countries (29–32). 
 
Individuals infected with XDR Salmonella Typhi have been successfully treated with 
azithromycin and meropenem (15). These antimicrobials remain effective treatment 
options, but their use is limited, as meropenem can only be given intravenously and both 
antimicrobials are often costly or not routinely available in many typhoid endemic 
countries (254,256). Also, of concern, this review identified multiple articles reporting 
azithromycin-resistant Salmonella Typhi in both Asia and Africa. We also identified two 
articles reporting meropenem-resistant Salmonella Typhi in Asia (107,243). To our 
knowledge, these reports of meropenem-resistance are the first reports of carbapenem-
resistance in Salmonella Typhi. Given the novel nature of these findings, and 
shortcomings in the reporting of the antimicrobial susceptibility testing undertaken; we 
recommend that these findings be further scrutinised, and confirmatory testing of the 
isolates be conducted. Reports of resistance to azithromycin and meropenem, and the 
recent outbreak of XDR typhoid in Pakistan, are a reminder of the possibility that typhoid 




1.4.3 Comparison with other studies 
The key findings of our review are consistent with findings from  
a previous systematic review of AMR Salmonella Typhi during the period 1973 through 
2018 (220) and a systematic review and meta-analysis of MDR and fluoroquinolone 
resistant enteric fever during the period 1990 through 2018 (257). These two and our 
review, each found that AMR Salmonella Typhi is increasing in typhoid endemic areas, 
with MDR Salmonella Typhi decreasing in Asia and increasing in Africa, and XDR 
Salmonella Typhi emerging in Asia. Each systematic review also showed a 
preponderance of studies of AMR Salmonella Typhi in South Asia, and data gaps in 
some other typhoid endemic regions, notably Central and Northern Africa, the Middle 
East, and Oceania. 
 
Our review differed from these earlier systematic reviews in a number of important ways. 
Both earlier reviews considered an isolate to be resistant to an antimicrobial if it was 
reported as ‘resistant,’ ‘intermediate,’ ‘intermediately susceptible,’ or ‘non-susceptible’ 
based on MIC or diameters of zones of inhibition via disc diffusion. We did not 
recategorize ‘intermediate,’ ‘intermediately susceptible,’ or ‘non-susceptible’ isolates as 
resistant, thus avoiding possible bias towards overestimating in the proportion of 
resistant isolates. The systematic review by Browne and colleagues required that 
studies reported susceptibility data on at least 10 isolates. Consequently, a number of 
studies presenting data on cephalosporin, meropenem, and azithromycin resistant 
Salmonella Typhi were excluded. In contrast, we did not require a minimum number of 
isolates be reported for studies to be included in our review and therefore observed 
earlier resistance to these antimicrobials. Furthermore, the systematic review by Browne 
and colleagues imputed study dates when these were not provided. Due to the often-
lengthy delay between isolate collection and article publication, we excluded articles 
where study dates were not provided in order to prevent misattribution of resistant 
isolates to the wrong time period. By not recategorizing intermediate isolates, restricting 
studies to those that reported susceptibility of a minimum number of isolates, limiting the 
antimicrobials on which resistance data were abstracted, or imputing study dates, our 
review presents appropriate raw data that are readily accessible to decision makers. 
 
1.4.4 Study limitations  
Our study had several limitations. First, a number of included articles did not directly 
report data on resistant Salmonella Typhi isolates. Many included articles reported only 
the number of susceptible Salmonella Typhi isolates, or provided only the proportion and 
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total isolates tested, thus, we inferred the proportion of resistant isolates at some study 
sites. There may be minor inconsistencies between the inferred and the true values.  
 
Second, a substantial number of included articles did not report which interpretive 
criteria were used to classify antimicrobial susceptibility testing results. This incomplete 
reporting of antimicrobial susceptibility testing methods is likely to introduce bias into our 
study and may be indicative of lower quality laboratory processes in some areas. 
However, it may also reflect a lack of guidelines for publishing microbiologic data. Going 
forward, adherence to the recently published Microbiology Investigation Criteria for 
Reporting Objectively (MICRO) has the potential to reduce this source of bias and 
enhance future AMR surveillance and research (258).  
 
Third, we combined antimicrobial susceptibility testing results classified using 
interpretive criteria for different methods. Among articles included in this review, the use 
of various antimicrobial susceptibility testing methods (e.g., disk diffusion, broth 
microdilution, agar dilution, E-test, etc.) was reported, and 9 (4.5%) of 198 articles did 
not report which methods were used. We acknowledge, that interpretive criteria differ 
for antimicrobial susceptibility testing results generated using different antimicrobial 
susceptibility testing methods, and inhibitory zone sizes may not always correlate well 
with MIC values (259). Furthermore, there may be variation in results of the same nature 
generated using different antimicrobial susceptibility testing methods. For example, we 
acknowledge that broth microdilution is the internationally recognised reference method 
for MIC determination and our inclusion of MICs generated by other methods (e.g., agar 
dilution and E-test) may be considered a limitation (260). We also recognise that there 
may have been some variation in the performances of the antimicrobial susceptibility 
tests performed by different scientists across the different study sites, and that isolates 
may have been misidentified as Salmonella enterica, or incorrectly serotyped as 
Salmonella Typhi.  
 
Fourth, we combined antimicrobial susceptibility testing results classified using 
interpretive criteria published by different groups (e.g., CLSI and EUCAST). Despite 
antimicrobial susceptibility testing being important for the clinical management of 
infection and AMR surveillance, interpretive criteria published by different groups often 
differ for the same pathogen-antimicrobial combinations (53,261). Consequently, where 
there are differences between the interpretive criteria published by different groups, the 
classification of an isolate as susceptible, intermediately susceptible, or resistant, may 




Fifth, included articles reported the use of antimicrobial susceptibility testing interpretive 
criteria published by individual groups in different years. Interpretive criteria breakpoints 
are set on the basis of the pharmacodynamic and pharmacological properties of the 
antimicrobial, clinical outcome data, and MIC data for the specific pathogen-
antimicrobial combination in question (262,263). After an antimicrobial has been in 
clinical use for some time, signals may arise that suggest the current interpretive criteria 
no longer meet clinical needs or reflect patient response to therapy. Consequently, 
revisions are often made to published interpretive criteria over time (53). By way of 
example, many revisions have been made to CLSI interpretive criteria relevant to 
Salmonella Typhi since 2010; notably, ceftriaxone, cefixime, and meropenem in 2010, 
and ciprofloxacin and ofloxacin in 2012 (13). In addition, CLSI interpretive criteria for 
Salmonella Typhi did not include breakpoints for azithromycin until 2015 (13). As most 
revisions to date have involved lowering the susceptible breakpoint, the prevalence of 
resistant isolates will likely be higher when using more recently determined interpretive 
criteria, even in instances where the quantitative antimicrobial susceptibility testing 
results are identical (53). Consequently, we may have overestimated the prevalence of 
resistance to fluoroquinolones and extended-spectrum cephalosporins in recent time 
periods compared with earlier time periods. In light of these considerations, it would have 
been beneficial to have reinterpreted antimicrobial susceptibility testing results using the 
most current interpretive criteria published by a single group. However, as we did not 
have access to MIC and inhibitory zone size values, such reinterpretations were not 
possible.  
 
Sixth, a large proportion of included articles reported microbiology laboratory data from 
urban hospitals. As AMR is associated with treatment failure and more severe illnesses 
requiring advance clinical care, those with resistant infections are more likely to seek 
hospital-based care (1,10,12). Conversely, those with mild illness caused by susceptible 
infections are more likely to be treated successfully in the community and less likely to 
seek hospital-based care. Furthermore, restricting this review to include only isolates 
from normally sterile sites may have introduced selection bias by only allowing isolates 
tested at institutions with the resources necessary to perform more complex laboratory 
tests (251,264). This restriction may also have meant that some earlier reports in the 
literature did not meet the inclusion criteria for this review. The greater proportion of 
hospital-based studies than community-based studies in this review may have led to 
overestimations of the prevalence of AMR infections as individuals with less severe 
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illnesses, including illnesses caused by antimicrobial susceptible Salmonella Typhi, 
would have been less likely to seek hospital-based care (265). 
 
Seventh, study sites were predominately located in Asia and Africa. Indeed, India, 
Pakistan, and Nepal, represented more than half of the study sites included. The 
distribution of included studies skewed toward three countries and Asia more generally. 
Underrepresented in this review were study sites from America and Europe. This is likely 
due to low typhoid incidence in these UN regions (1), and HICs generally relying on 
national surveillance and reporting systems rather than peer-reviewed journals to 
disseminate data on AMR (265). Data in such national surveillance and reporting 
systems are often not in the public domain and, as such, a potential key source of 
information about AMR typhoid was not included in our review. We also did not include 
publicly available antimicrobial susceptibility testing results collected by national 
surveillance networks, such as the European Centre of Disease Control’s Surveillance 
Atlas(http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/ 
database.aspx) and the United States’ National Antimicrobial Resistance Monitoring 
System (https://cdc.gov/narms/reports/index.html). The omission of AMR typhoid data 
from these UN regions, consisting mainly of HICs, is unlikely to greatly impact the 
meaningfulness of our findings, as risk factors for typhoid in HICs are few, and most 
typhoid illnesses in HICs are related to travel from LMICs (1). Notably, there was also 
an absence of study sites in Oceania despite the urgent need to understand typhoid 
epidemiology, including AMR, in the region (266). This is especially true as some models 
suggest that typhoid incidence is higher in Oceania than Asia and Africa (267).  
 
Finally, although we aimed to be as inclusive as possible, due to pragmatic and logistical 
constraints, we may have missed some relevant articles. We were limited by the 
language abilities of our team of investigators who were fluent only in English, French, 
Kiswahili, Bahasa Malaysia, and Mandarin. Articles written in other languages may have 
been less likely to have been included, as were older articles from which text could not 
be easily translated via online translation tools. This may have, in particular, limited 
important results reported in Asian languages other than Bahasa Malaysia and 
Mandarin. As our database searches identified articles based on the presence of specific 
indexed terms (45), we likely missed articles that included AMR data, but not as a 
primary outcome. In Addition, the full text of 29 articles that met our inclusion criteria at 
the title and abstract screening stage of this review could not be retrieved and were 




1.4.5 Future directions 
Our finding of widespread and increasing AMR typhoid in Asia and Africa reaffirms the 
importance of interventions to reduce inappropriate antimicrobial use, and measures to 
control typhoid. Inappropriate antimicrobial use in community and healthcare settings is 
an important driver of AMR (11). In acknowledgement of this, the WHO and others 
recommend surveillance of antimicrobial use, and dedicated AMS activities and policies 
to promote the appropriate use of antimicrobials (268–270). Local antimicrobial 
surveillance data can be useful for identifying changes in AMR among locally circulating 
pathogens, and can meaningfully inform empiric treatment guidelines for fever and other 
syndromes (14). Evidence-based AMS programmes and policies can further contribute 
to reducing inappropriate antimicrobial use through improving initial prescribing 
practices, including antimicrobial choice and documentation, and encouraging clinicians 
to review or stop treatments upon the availability of additional information (e.g., 
microbiological laboratory data) which may have changed the appropriate care from 
what was initially given (268,271). Policies that regulate the sale and use of 
antimicrobials in the community, such as preventing the sale of antimicrobials over the 
counter without a prescription, are also important for reducing inappropriate 
antimicrobial use and AMR (271). Through reducing inappropriate antimicrobial use, it 
is hoped that current treatment options are preserved, and illnesses resistant to 
available antimicrobial treatments avoided or delayed until new antimicrobials are 
developed (272).  
 
Ensuring access to improved sanitation, and microbiologically safe water and food, has 
long been recognised as the most important measure for typhoid control. Improvements, 
particularly in the microbiological quality of water in many places has be associated with 
a substantial decrease in typhoid incidence (273), and large outbreaks of typhoid, such 
as the 1997 outbreak of typhoid in Tajikistan, have been controlled with efforts to 
improve the microbiologic quality of drinking water (274). However, the political will and 
financial resources to scale up sanitation and water infrastructure interventions are low 
(275). It is likely that contamination of water sources with Salmonella Typhi will maintain 
typhoid in endemic areas, and other control measures will be necessary to reduce the 
impact of AMR typhoid (275). 
 
Typhoid vaccines are an important typhoid control measure which may also reduce the 
use of antimicrobials for treating suspected typhoid illnesses. In 2017, the WHO SAGE 
Working Group on Typhoid Vaccines re-emphasised the importance of typhoid vaccines 
for tackling increasing AMR typhoid, particularly in LMICs (41). Subsequently, the WHO 
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released a position paper recommending the use of the new typhoid conjugate vaccine 
in children 6 months of age or older in countries where typhoid is endemic, with priority 
given to countries with a high typhoid incidence or AMR Salmonella Typhi (38). This is 
the first time that a vaccine has been recommended by the WHO on the basis of 
containing the spread of an AMR pathogen (38). 
 
Gavi, the Vaccine Alliance, a major funder of vaccines in low-income countries, has 
committed $85 million toward the rollout of typhoid conjugate vaccines and pledged to 
support Gavi-eligible countries to introduce this new typhoid conjugate vaccine into 
routine immunisation schedules (37). In November 2019, Pakistan, where there is an 
ongoing outbreak of XDR typhoid, became the first country to introduce the new typhoid 
conjugate vaccine into their routine immunisation programme with support from Gavi. 
Liberia and Zimbabwe are also preparing to introduce the typhoid conjugate vaccine, 
and several other countries are currently assessing data on the incidence of typhoid in 
their countries and considering using the vaccine (276). Further support will be 
necessary for non-Gavi-eligible countries, recognising that many of these countries, 
which have fragile health systems and constrained immunisation budgets, could also 
have high typhoid incidence and AMR Salmonella Typhi (277). 
 
1.4.6 Conclusion 
AMR Salmonella Typhi is prevalent in Asia and Africa, and resistance has emerged to 
each of the principal antimicrobial agents used to treat typhoid. MDR Salmonella Typhi 
is established in Asia and is emerging in Africa. XDR Salmonella Typhi is also an 
emerging threat in Asia, and it is likely that this phenotype will also be observed in Africa 
in due course. AMR Salmonella Typhi poses a substantial threat to global health, and 
has led to increased treatment costs, severity of illness, and higher case fatality 
(256,278). Interventions to promote appropriate antimicrobial use, and typhoid control 
measures should be expanded. Implementing robust AMS and surveillance 
programmes will slow the spread of AMR caused by inappropriate antimicrobial use. 
Local antimicrobial susceptibility testing data should be used to inform empiric treatment 
decisions. Improving access to microbiologically safe water and food and introducing 
TCV into routine immunisation programmes in areas of high typhoid incidence and 
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2. Chapter 2 
Survey of healthcare seeking behaviour 
and medicine use among individuals with 
fever in Yangon Region, Myanmar, 2018 
2.1 Introduction 
2.1.1 Rationale 
Fever is one of the most common reasons for seeking healthcare in the South-eastern 
Asia region (1,2). There are many infectious causes of fever and in the absence of 
localising symptoms it can be difficult to distinguish these causes from one another 
without reliable rapid diagnostic tests or clinical laboratory testing; resources that are 
often scarce in low- and middle-income countries (LMICs) (3,4). Unlike other syndromes, 
such as pneumonia and diarrhoea, that have well defined global burden of disease 
estimates, to date a comprehensive approach has not been applied to describing the 
global burden of febrile illness (5). Consequently, the relative importance of each cause 
of fever is seldom well understood at the community level, and data on the major causes 
of fever in many countries in South-eastern Asia, including Myanmar, are limited (3,6).  
 
A systematic review of the infectious causes of febrile illnesses among patients in 
Southern and South-eastern Asia found that viral infections predominated, followed by 
bacterial infections, and malaria (3). A recent study of persons ≥12 years of age with 
fever seeking healthcare at Yangon General Hospital, Myanmar, found that 
approximately one-third of individuals with fever received an initial diagnosis of 
‘unspecified fever’ (7). The 2015-2016 Myanmar Demographic and Health Survey (DHS) 
found that fever was the most common childhood illness nationwide, with a two-week 
period prevalence of 16.0% among infants and children <5 years of age (8). Two-week 
period prevalence of fever is often used as an indicator of malaria risk. However, Prasad 
and colleagues found only a weak association between two-week fever prevalence and 
country-level malaria risk as measured by the Malaria Atlas Project (5). The authors 
hypothesised that, while fever prevalence did increase with malaria risk, other drivers of 
fever prevalence, including non-malaria infections, may play an important role (5).  
 
Due to the variety of possible causes of fever, pragmatic clinical management requires 
clinicians to assess the severity of febrile illnesses, based on key features of clinical 
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history and physical examination, and apply knowledge about the probable local causes 
of fever, when making treatment decisions (9,10). Individuals with severe febrile 
illnesses are often treated in hospitals, and clinical management guidelines recommend 
immediate empiric treatment that may include the use of antibacterials and other 
antimicrobials (10,11). In this setting, antimicrobial treatment choices may be made that 
do not match common aetiologies of fever (12,13). It has been shown that such 
imprudent antimicrobial use contributes to the emergence of antimicrobial resistance 
(AMR) and spread of resistant organisms into the community (4,14).  
 
Most febrile illnesses are mild and are treated in the community (12). As there are many 
causes of fever and many mild febrile illnesses are caused by self-limited infections, 
clinical management guidelines recommend that clinicians test individuals with mild 
febrile illness for malaria and other infectious causes before administering antimalarials, 
antibacterials, or other antimicrobials (10). However, when diagnostic tests are 
unavailable or do not identify a specific cause of fever, clinicians often treat patients 
according to local syndrome-based clinical management guidelines (10,11,15). Reliance 
on these guidelines has been shown to result in overuse of antimicrobials in the 
community by patients who do not need them (4,16). Additionally, antimicrobials are 
available in the community without consulting a medically-trained healthcare provider 
and are often used by individuals who likely receive limited therapeutic benefit (17). 
Controlling the use of antimicrobials in the community is necessary to slow the 
emergence and spread of AMR (12,18). 
 
In Myanmar, the healthcare system consists of both public and private healthcare 
providers, and patients can ostensibly choose to seek healthcare from any healthcare 
provider that they wish (19). The Myanmar Ministry of Health and Sports (MoHS) is the 
major provider of public healthcare and administers most public hospitals and public 
primary care centres (20). Some other Ministries provide healthcare to specific groups 
of Myanmar society in hospitals and primary care centres that they administer with their 
own staff and budgets. For example, healthcare for military personnel and their families 
is overseen by the Myanmar Ministry of Defence (20,21). Private healthcare in Myanmar 
is provided by privately-owned and operated hospitals, primary care centres, 
pharmacies, and informal healthcare providers (e.g., street drug markets and vendors) 
(21). Traditional medicine, consisting mainly of the dispensing of herbal medicines, 
massage, warm compresses, and hot oil application, is also practised in Myanmar 
(19,22). Traditional medicine is predominantly provided by privately-owned and 
operated traditional medicine providers, but may also be provided in public and private 
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primary care centres and hospitals (20). Research indicates that traditional medicine is 
more accepted in rural areas than in urban areas (19,20). 
 
Public healthcare in Myanmar is nominally free at the point of care (21). However, 
individuals seeking healthcare from public hospitals and primary care centres often incur 
unpredictable out-of-pocket healthcare costs due to decades of low government 
healthcare expenditure and international monetary policies that promoted 
decentralisation of the healthcare system and healthcare cost recovery (19,21,23). 
Qualitative studies have shown that many individuals prefer to seek healthcare from 
private hospitals and primary care centres due to greater certainty about healthcare 
costs, as well as shorter wait times, and a perception of higher quality healthcare 
compared with public healthcare providers (20,21). High out-of-pocket healthcare costs 
for formal healthcare in Myanmar mean that approximately 16.0% of Myanmar 
households face catastrophic healthcare expenditure, defined as expenditure ≥10% of 
their total expenditure on healthcare, annually (24,25). Consequently, individuals who 
cannot afford formal healthcare may choose to not seek healthcare or to seek healthcare 
from informal healthcare providers (26,27). Other non-cost related factors, such as 
longer opening hours, greater stock of medicines, geographical closeness, and more 
rapid service compared with formal healthcare providers may lead individuals with fever 
to seek healthcare from informal healthcare providers (28). 
 
Healthcare seeking behaviour for fever is an important surrogate for estimating 
healthcare seeking behaviour for other diseases, and healthcare utilisation surveys can 
provide insight into whether the healthcare system is functioning effectively (29–31). 
Currently, data on the healthcare seeking behaviours of individuals in Myanmar are 
scarce. More information about healthcare seeking behaviours could be used to improve 
the availability and use of formal healthcare, and to identify targets for improving the 
prudent use of antimicrobials in the community setting (8,31).  
 
2.1.2 Study Aim 
We sought to describe healthcare seeking behaviour and medicine use among 





2.2.1 Study design 
Our study was part of a tripartite project involving researchers from University of 
Medicine 1, Yangon, Myanmar; University of Health Sciences of Lao PDR, Vientiane, 
Lao PDR; and University of Otago, Dunedin, New Zealand. The larger project sought to 
estimate the incidence of fever due to specific causes including enteric fever, scrub 
typhus, and leptospirosis, and to describe patterns of healthcare seeking among 
individuals with fever in the catchment areas of Mahosot Hospital, Lao PDR, and Yangon 
General Hospital, Myanmar (32). Study design, sample size estimation, and household 
selection followed the method described in the World Health Organization (WHO) 
vaccination coverage cluster survey manual (33) and adapted widely used 
questionnaires on healthcare utilisation (31,34–36). Researchers from all three 
institutions were involved in survey design but only researchers from University of 
Medicine 1, Yangon, Myanmar, and University of Otago, Dunedin, New Zealand were 
involved in data collection in Yangon, Myanmar. I was not involved in study design or 
data collection but completed data cleaning and analyses of the Myanmar data 
presented in this thesis. 
 
2.2.2 Study setting 
Myanmar is a lower-middle income country in South-eastern Asia which had a 
population of 51,486,253 during the 2014 Myanmar Population and Housing Census 
(37). The Yangon Region, with a population of 7,360,703, is the most populous 
administrative region in Myanmar (37). It is also the most urban administrative region in 
Myanmar with 5,160,512 (70.2%) of the 7,360,703 individuals living in wards, the 





Figure 2.1. Map of Southern and South-eastern Asia showing (A) Myanmar and (B) 
Yangon Region. Reprinted from Oo WT et al (32). 
 
2.2.3 Sample size estimation  
Sample size was determined to provide a precision of ±10.0% for the proportion of 
individuals with fever who sought healthcare at Yangon General Hospital, Yangon, 
Myanmar, and was based on the WHO vaccination coverage cluster survey method 
(33). Using the conservative prevalence estimate of 50.0%, 103 independent 
observations are needed. To achieve this effective sample size using the cluster survey 
design, researchers assumed an intra-cluster correlation coefficient of 0.33, yielding a 
design effect of 2.33, and chose to include a minimum of five households per ward. 
Based on these parameters, researchers estimated a minimum sample size of 240 
households. Subsequently, researchers assumed that 20% of households would have 
no one home after three return visits or would refuse to participate. Applying an inflation 
factor of 1.25 to the number of households to be surveyed, the researchers included 
seven households each from 48 wards, yielding a total sample of 336 households. 
 
2.2.4 Household selection 
Household selection was based on the two-stage cluster sampling design used by the 
WHO vaccination coverage cluster survey method (33). The primary sampling unit was 
the ward, and the secondary sampling unit was the household. The first stage of the 
two-stage cluster survey involved selecting 48 (7.0%) of 689 wards in Yangon Region 
using probability proportional to estimated size sampling. The estimated size of each 
ward was that enumerated in the 2014 Myanmar Population and Housing Census (37). 
In the second stage, seven households were selected from each ward using simple 
random sampling from a contemporary list of ward households maintained by municipal 
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offices in each jurisdiction. Consistent with the WHO vaccination coverage cluster 
survey definition, a household was defined as a group of individuals sharing a kitchen 
(33). Households were selected from a list of households in each ward obtained from 
the relevant Township Health Department. Dr Cheun Yen Hong, a statistician who was 
not a member of the research team, randomly selected wards and households for 
inclusion, and each data collector was assigned to survey specific households.  
 
2.2.5 Survey instrument 
A structured questionnaire (Appendix 2) was adapted from other widely used 
questionnaires of healthcare utilisation (31,34–36). The questionnaire was first prepared 
in English and translated into Burmese. It contained three sections: demographic 
characteristics of household members; healthcare seeking for fever; and socioeconomic 
status and barriers to healthcare seeking. Demographic characteristics of household 
members sought included the following: the age and sex of all usual household 
residents, including individuals who had died in the past 3 months; whether an individual 
had resided in the house for ≥6 months; and the relationship of the healthcare decision 
maker to the head of household. Healthcare seeking for fever was asked for any 
household member who experienced fever in the past three months. Fever was 
subjective as perceived by the head of household or healthcare decision maker. Details 
sought were: the number of days from fever onset to the date of interview; whether the 
individual was admitted to hospital for fever; whether the fever resolved, persisted, or 
led to death; history of infection; treatments obtained, and whether these treatments 
were medicines or other therapies; the names of any antibacterials obtained; and the 
provider of medicines. Questions relating to socioeconomic status and barriers to 
healthcare included the occupation and education level of the head of household; total 
household weekly expenditure; house ownership; household ownership of 23 different 
consumer assets (e.g., radio, car, etc.); electricity access; house ownership; and floor, 
wall, and roof construction materials of the house. Data on household weekly 
expenditure were collected in Myanmar Kyat (MMK) and also converted to United States 
Dollars (US$) based on the Central Bank of Myanmar exchange rate of the study 
midpoint, 23 March 2018 (38).  
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2.2.6 Pretesting  
Prior to data collection, members of the study team pretested the questionnaire by 
trialling it among themselves, and then among a small purposive sample of community 
members. Pretesting and validation were carried out to identify and correct problems 
with questionnaire design and logic, and to ensure that the questions would be clearly 
understood by study participants. 
 
2.2.7 Data collector selection and training 
Six local community health workers with prior data collection experience were employed 
to administer questionnaires and record data for the survey. Local community health 
workers are respected and trusted members of local communities in Myanmar, enabling 
them to collect data on sensitive topics such as health and income (39). Data collectors 
were trained to deliver the questionnaire in a two-day training session beginning on 8 
March 2018 led by Saw Thu Nandar, MHSc, a Myanmar national who was a Visiting 
Scientist, Department of Community and Global Health, University of Tokyo, Japan. 
During the training session, presentations and practice interviews were conducted to 
ensure that the data collectors had a thorough understanding of the questionnaire 
contents and were confident in consistently delivering the questionnaire. 
 
2.2.8 Data collection 
The data collectors visited each household, obtained informed consent, and interviewed 
the head of household or another healthcare decision maker using the structured 
questionnaire. All questionnaires were completed in Burmese. A head of household was 
defined as the ‘household member acknowledged by other household members as 
being usually responsible for the upkeep and maintenance of the household’ and a 
household healthcare decision maker was defined as a ‘household member ≥ 18 years 
of age, who was responsible for daily healthcare decisions for the entire household and 
its members.’ To obtain a completed questionnaire each household was visited up to 
three times. If there was no eligible person present after three visits, or if consent to 
participate was refused, the household was replaced with another randomly selected 
household from the same ward. 
 
2.2.1 Data management 
Completed questionnaires were returned to University of Medicine 1, Yangon, for 
storage and data entry. Data from the paper questionnaires were entered into a secure 
Excel spreadsheet (Microsoft Corporation, Redmond, WA, USA) by Ye Min Kyaw, the 
83 
 
supervisor of the data collection team. Uncleaned data were provided to me in April 2019 
and I imported these data into Stata, version 16.0 (StataCorp LLC, College Station, TX, 
USA) where I checked for logical inconsistencies. For each of the 71 variables coded 
for each of the 336 households and the 33 variables coded for each of the 1,598 
individuals in the dataset, I checked against the supplied data dictionary to identify any 
variables coded with an illogical value, or for which the value was missing. I also checked 
that coding was consistent for variables of the same type (e.g., were all of the 
dichotomous variables coded as ‘0’ no and ‘1’ yes?). During this process a large number 
of errors were uncovered. Consequently, I corresponded extensively with the supervisor 
of the data collection team, via email, phone, and in-person. As the questionnaires were 
completed in Burmese, the supervisor of the data collection team compared responses 
on the questionnaire forms with those coded in the data file and discussed with me any 
discrepancies. Dr Win Thandar Oo (PhD Student, Centre for International Health, 
University of Otago) assisted with translating verbal and written communication with the 
supervisor of the data collection team. 
 
2.2.2 Statistical analyses 
Descriptive analyses 
I described household socio-economic characteristics as numbers and proportions. I 
also described the numbers and proportions of individuals with fever who sought 
healthcare from different healthcare providers, which medicines they used for fever, and 
from which healthcare providers they obtained antibacterials. I classified hospitals, 
primary care centres, and pharmacies as ‘formal healthcare’ and street markets or 
vendors as ‘informal healthcare’. I further stratified ‘formal healthcare’ providers into 
‘public healthcare providers’ and ‘private healthcare providers’; ‘public healthcare 
providers’ were those administered by the Myanmar Ministry of Health and Sport, and 
‘private healthcare providers’ were those administered by private individuals or 
companies. Because of the two-stage sampling method, sample weights were 
calculated and applied so that results concerning individuals would be representative of 
individuals in the Yangon Region population. Thus, these results were presented as 
numbers and proportions with 95% confidence intervals (95% CI). 
 
Wealth index construction 
One of the household socio-economic characteristics used to describe study participants 
was a wealth index constructed using principal components analysis (PCA). I 
constructed the wealth index following the method developed by Rutstein and 
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colleagues for analysing data collected using the DHS method (40,41). This method is 
based on the work of Filmer and Pritchett (42), and was used to consolidate a set of 
binary potential wealth indicator variables into a single variable as a proxy for a 
household’s long-term wealth (41). I used the responses on 28 potential wealth 
indicators to construct the wealth index. These potential wealth indicators were a 
household’s ownership of 23 different consumer assets (e.g., radio, car, etc.); electricity 
access; house ownership; and house floor, wall, and roof construction materials 
(Appendix 2). 
 
The PCA was performed using binary variables. Responses to questions about the 
ownership of household assets, electricity access, and house ownership were naturally 
binary. Responses to questions about floor, wall, and roof construction materials were 
nominal categorical variables and hence have no natural order. That is, there is no 
particular reason that the value [7] used to represent ‘bamboo floor’ in our dataset is a 
higher number than the value [1] used to represent ‘brick floor’. Including such 
categorical variables in the PCA would have distorted the results in favour of responses 
coded with higher numbers (40). Therefore, consistent with the DHS method, I recoded 
each categorical variable as a set of binary dummy variables. I combined the natural 
construction materials (i.e., earth, sand, and dung) into a single ‘natural construction 
material’ dummy variable (40). I ran the frequencies on all newly created variables, 
compared these with the frequencies in the original dataset, and corrected any 
discrepancies.  
 
I calculated the mean and standard deviation for all binary variables, including the binary 
dummy variables, to determine variables that had very little or no variation. I excluded 
variables that had very little or no variation, and using the Stata PCA command, 
conducted the PCA using all remaining binary variables. Consistent with the DHS 
method, I took the first principal component to be the wealth index and, using the Stata 
predict command, created a wealth index score for each household. The wealth index 
score was the sum of first principal component weights for the presence or absence of 
each potential wealth indicator. The first principal component weights reflected the 
importance of each potential indicator for predicting wealth; potential wealth indicators 
that were more unequally distributed across the sample contributed a greater weight in 
the principal component. I then grouped households into quintiles of equal proportions 
based on these values. Finally, I checked that each variable was related to the wealth 
quintiles in the expected directions. For example, I confirmed that percentage of 




I used logistic regression to explore the independent associations between explanatory 
variables and the healthcare seeking behaviours of individuals with fever. Specifically, I 
explored the differences between individuals with fever who sought ‘formal healthcare’ 
versus ‘informal healthcare,’ and the differences between individuals with fever who 
sought ‘public healthcare’ versus ‘private healthcare’. In both analyses the explanatory 
variables were the demographic and household socio-economic characteristics of 
individuals with fever. I expected that there would be multi-collinearity between some 
explanatory variables. Therefore, I checked correlations between explanatory variables 
and, where the correlation between characteristics was high, I included only one of two 
variables in my logistic regression model. My decisions on which explanatory variables 
to retain in the model were based on epidemiological considerations informed by 
previous studies of healthcare utilisation. I applied sample weights to variables included 
in the logistic regression and produced univariable and adjusted ORs with 95% CIs and 
p-values. The significance level of each association was tested using the Wald test and 
a significance level of p≤0.05 was deemed statistically significant.  
 
2.2.3 Research ethics 
Written informed consent was obtained from each head of household or healthcare 
decision maker before data were collected. Ethics approval for our survey was obtained 
from the ethics committee of the Department of Medical Research, Yangon, Myanmar; 
and the University of Otago Human Ethics Committee (Health), Dunedin, New Zealand.  
 
2.3 Results 
Data collection was conducted in Yangon, Myanmar, from 12 March 2018 through 5 
April 2018. A total of 336 households comprising 1,598 individuals agreed to participate; 
57 (16.9%) households had no head of household or healthcare decision maker at home 
after three return visits or refused to participate. These households were replaced with 
another randomly selected household from the same ward.  
 
2.3.1 Socio-economic characteristics of households  
‘A total of 211 (62.8%) of 336 heads of households included in our survey were 
employed and 222 (66.0%) had an education level of more than primary school. Weekly 
household expenditure ranged from <K25,000 (<US$18.70) to ≥K75,000 (≥US$59.10); 
147 (43.8%) of 336 households had a weekly household expenditure of K25,000 to 
K49,999 (US$18.70 to US$36.39) (Table 2.1).  
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Table 2.1. Socio-economic characteristics of all participating households, survey 
of healthcare seeking behaviour and medicine use among individuals with fever 
in Yangon Region, Myanmar, 2018 (N = 336) 
Characteristics n (%) 







Head of household education level   















Household weekly expenditure a   
(MMK) (US$)    
<K25,000 
K25,000 to K49,999 
K50,000 to K74,999 
≥K75,000 
<$18.70 
$18.70 to $36.39 










a MMK, Myanmar Kyat; US$, United States Dollar. 1.00 US$ = 1,337 MMK, 23 March 
2018 [Source: Central Bank of Myanmar (38)]. 
 
2.3.2 Wealth index construction 
Of 336 households included in our survey, 335 (99.7%) provided responses to the 
questions about socio-economic conditions. Of these, 331 (98.8%) owned at least one 
mobile telephone, 330 (98.5%) had electricity access, two (0.6%) owned an ox, and 
none (0.0%) owned a boat (Table 2.2). Wealth indicators possessed by <10 or >225 
households were excluded due to having little or no variation between households. The 
remaining wealth indicators were included in the PCA. The first component of the PCA 
had an eigenvalue of 4.7 and accounted for 16.9% of total variation across households. 
The PCA derived weights for each wealth indicator ranged from -0.307 for natural walls 
to 0.288 for bed. Each household had a PCA derived wealth index score from -5.899 
through 3.8101 (Table 2.3 and Figure 2.2).  
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Table 2.2. Possession of wealth indicators among all participating households, 
survey of healthcare seeking behaviour and medicine use among individuals with 
fever in Yangon Region, Myanmar, 2018 (N = 336) 
Wealth 
indicator 
Possession, n (%) a 
Mean SD 
PC1 
weight No Yes 
Radio  297  (88.7) 38  (11.3) 0.113 0.318 0.073 
Television  17  (5.1) 318  (94.9) 0.949 0.220 0.207 
Internet  74  (22.1) 261  (77.9) 0.779 0.416 0.177 
Car 283  (84.5) 52  (15.5) 0.155 0.363 0.211 
Boat  335  (100.0) 0  (0.0) 0 0 - 
Motorbike  256  (76.4) 79  (23.6) 0.236 0.425 -0.018 
Ox  333  (99.4) 2  (0.6) 0.006 0.077 - 
Mattress  178  (53.1) 155  (46.3) 0.463 0.499 0.279 
Dining table  52  (15.5) 283  (84.5) 0.845 0.363 0.188 
Refrigerator  80  (23.9) 255  (76.1) 0.761 0.427 0.279 
Fan  45  (13.4) 290  (86.6) 0.866 0.342 0.144 
Tape player 68  (20.3) 267  (79.7) 0.797 0.403 0.180 
Computer  262  (78.2) 73  (21.8) 0.218 0.413 0.239 
Mobile telephone 4  (1.2) 331  (98.8) 0.988 0.109 - 
Truck  322  (96.1) 13  (3.9) 0.039 0.193 0.075 
Bicycle  140  (41.8) 195  (58.2) 0.582 0.494 -0.011 
Bed  175  (52.2) 160  (47.8) 0.478 0.500 0.288 
Bed net  8  (2.4) 327  (97.6) 0.976 0.153 - 
Chair  38  (11.3) 297  (88.7) 0.887 0.318 0.234 
Freezer  316  (94.3) 19  (5.7) 0.057 0.232 0.080 
Sewing machine  220  (65.7) 115  (34.3) 0.343 0.476 0.089 
Iron  12  (3.6) 323  (96.4) 0.964 0.186 0.078 
Bank account 182  (54.3) 153  (45.7) 0.457 0.499 0.268 
Electricity  5  (1.5) 330  (98.5) 0.985 0.121 - 
Owns house 58  (17.3) 277  (82.7) 0.827 0.379 0.114 
Natural floors 202  (60.3) 133  (39.7) 0.397 0.490 -0.301 
Brick floors 306  (91.3) 29  (8.7) 0.087 0.282 0.019 
Cement floors 227  (67.8) 108  (32.2) 0.322 0.468 0.118 




Table 2.2 (continued). 
Natural walls 214  (63.9) 121  (36.1) 0.361 0.481 -0.307 
Brick walls 276  (82.4) 59  (17.6) 0.176 0.382 0.006 
Cement walls 191  (57.0) 144  (43.0) 0.4230 0.496 0.280 
Tile walls 326  (97.3) 9  (2.7) 0.027 0.162 - 
Metal walls 333  (99.4) 2  (0.6) 0.006 0.077 - 
Brick roof 329  (98.2) 6  (1.8) 0.018 0.133 0.020 
Metal roof 6  (1.8) 327  (97.6) 0.982 0.133 - 
SD, standard deviation. PC1, first principal component. a One household is missing a 
wealth quintile as they were excluded from the principle component analysis due not 
providing any data on asset ownership. 
 
Table 2.3. Wealth index scores by quintile, survey of healthcare seeking behaviour 
and medicine use among individuals with fever in Yangon Region, Myanmar, 2018 




Mean SD Minimum Maximum 
Quintile 1 (poorest) 67 -3.227 1.076 -5.899 -1.961 
Quintile 2  67 -1.170 0.446 -1.958 -0.385 
Quintile 3  67 0.165 0.365 -0.380 0.759 
Quintile 4  67 1.421 0.359 0.772 2.017 
Quintile 5 (richest) 67 2.812 0.512 2.048 3.811 
SD, standard deviation. a One household is missing a wealth quintile as they were 






Figure 2.2. Wealth index scores by wealth quintile, survey of healthcare seeking 
behaviour and medicine use among individuals with fever in Yangon Region, 
Myanmar, 2018 (N = 336).  
One household is missing a wealth quintile as it was excluded from the principle 
component analysis due not providing data on asset ownership. A higher wealth index 
score indicates greater long-term wealth. Vertical lines represent the cut-off values for 
each wealth quintile.  
 
2.3.3 Characteristics of individuals with fever compared with individuals without 
fever 
In our univariable analysis, the odds of having fever compared with not having fever 
were 6.04 (95% CI: 3.64, 10.0; p = <0.001; Table 2.4) times greater for infants and 
children <5 years compared with individuals ≥12 years of age. For children 5 to 11 years 
of age compared with individuals ≥12 years of age, the odds ratio of having fever versus 
not having fever was 2.38 (95% CI: 1.52, 3.74; p = <0.001). This trend indicates that the 
odds of having fever decrease with increasing age. 
 
We found no evidence of a difference in odds of having fever versus not having fever 
between female and male individuals (OR = 0.99; 95% CI: 0.14, 1.35; p = 0.94). We also 
found no evidence of a difference in odds of having fever versus not having fever 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
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between individuals whose head of household was employed and individuals whose 
head of household was unemployed (OR = 1.06; 95% CI: 0.78, 1.43; p = 0.71).  
 
The odds of having fever compared with not having fever were 0.33 (95% CI: 0.11, 0.95, 
p = 0.04) for individuals whose head of household’s education level was middle school 
compared with individuals whose head of household’s education level was primary 
school or less. Compared with individuals whose head of household’s education level 
was primary school or less, the odds ratios of having fever versus not having fever were 
0.78 (95% CI: 0.53, 1.14; p = 0.19) for individuals whose head of household’s education 
level was high school. The odds of having fever versus not having fever were 1.05 (95% 
CI: 0.66, 1.65; p = 0.84) greater for individuals whose head of household’s education 
level was high school compared with individuals whose head of household’s education 
level was primary school or less. The odds of an individual whose household weekly 
expenditure was ≥K75,000 (≥US$59.10) having fever versus not having fever were 0.62 
(95% CI: 0.35, 1.10, p = 0.10) compared with individuals whose household weekly 
expenditure was <K25,000 (<US$18.70). For individuals from a household in Quintile 5, 
the richest quintile, compared with individuals in Quintile 1, the poorest quintile, the odds 
ratio for having fever versus not having fever was 0.85 (95% CI: 0.54, 1.33, p = 0.46; 
Table 2.4). 
 
Table 2.4. Univariable analysis of predictors of individuals having fever versus not 
having fever, survey of healthcare seeking behaviour and medicine use among 
individuals with fever in Yangon Region, Myanmar, 2018 (N = 1,598) 
Characteristics 
Fever Univariable analysis 
Yes No OR (95% CI) p-value 
Age      
<5 years 














































Table 2.4 (continued). 
Head of household education level a      
























Household weekly expenditure b      
(MMK) (US$)      
<K25,000 
K25,000 to K49,999 
K50,000 to K74,999 
≥K75,000 
<$18.70 
$18.70 to $36.39 






















Household wealth quintile c      






























a Individuals from six households were excluded from head of household education level 
as response was ‘unknown’. b MMK, Myanmar Kyat; US$, United States Dollar. 1.00 
US$ = 1,337 MMK, 23 March 2018 [Source: Central Bank of Myanmar (38)]. c One 
household of three individuals is missing a wealth quintile as they were excluded from 
the principle component analysis due not providing any data on asset ownership. 
 
2.3.4 Healthcare seeking behaviour of household members with fever 
Of the 237 individuals with fever included in our survey, 174 (73.1%; 95% CI: 65.9%, 
79.2%) sought formal healthcare. The most commonly used healthcare provider type 
was a private healthcare centre; a total of 150 (62.7%; 95% CI: 56.0%, 69.0%) of 237 
individuals with fever sought healthcare from a private primary care centre. A total of 63 
(26.9%; 95% CI: 20.9%, 31.1%) individuals with fever sought informal healthcare, and 
none (0.0%) sought healthcare from a traditional medicine provider. Of the two specific 
healthcare providers coded in our data set, 1 of 237 individuals with fever (0.4%; 95% 
CI: <0.01%, 0.03%) sought healthcare from Yangon General Hospital, and 5 of 237 





Table 2.5. Healthcare seeking behaviour of individuals with fever, survey of 
healthcare seeking behaviour and medicine use among individuals with fever in 
Yangon Region, Myanmar, 2018 (N = 237) 
Type of healthcare provider first visited for fever n Proportion, (95% CI) a 
Formal healthcare provider 
Public primary care centre 
Public hospital  
Private primary care centre 
Private hospital 
Private pharmacy 
Informal healthcare provider 

























a Proportions are percentages weighted to the Yangon Region population. 
 
2.3.5 Univariable analysis of predicators of seeking formal versus informal 
healthcare 
In our univariable analysis, the odd ratio of seeking formal versus informal healthcare 
was 4.49 (95% CI: 1.42, 14.2; p = 0.01) for infants and children <5 years of age with 
fever compared with individuals ≥12 years of age with fever. The odds ratio of seeking 
formal versus informal healthcare was 0.33 (95% CI: 0.11, 0.95, p = 0.04) for individuals 
with fever whose head of household’s education level was middle school compared with 
individuals with fever whose head of household’s education level was primary school or 
less. Compared with individuals with fever whose head of household’s education level 
was primary school or less, the odds of seeking formal versus informal healthcare were 
0.55 (95% CI: 0.19, 1.58; p = 0.26) for individuals with fever whose head of household’s 
education level was high school and 0.64 (95% CI: 0.23, 1.78; p = 0.39) for individuals 
with fever whose head of household’s education level was university.  
 
We found no evidence of a statistically significant difference in odds of seeking formal 
versus informal healthcare by sex, head of household employment, household 




Table 2.6. Univariable analysis of predictors of individuals with fever seeking 
formal versus informal healthcare, survey of healthcare seeking behaviour and 






Yes No OR (95% CI) p-value 
Age      
<5 years 











































Head of household education level a      
























Household weekly expenditure b      
(MMK) (US$)      
<K25,000 
K25,000 to K49,999 
K50,000 to K74,999 
≥K75,000 
<$18.70 
$18.70 to $36.39 

























Table 2.6 (continued). 
Household wealth quintile c      






























a Six individuals are missing a head of household education level as response was 
‘unknown’. b MMK, Myanmar Kyat; US$, United States Dollar. 1.00 US$ = 1,337 MMK, 
23 March 2018 [Source: Central Bank of Myanmar (38)]. c One household is missing a 
wealth quintile as they were excluded from the principle component analysis due not 
providing any data on asset ownership. 
 
2.3.6 Multivariable analysis of predicators of seeking formal versus informal 
healthcare 
In our multivariable analysis, the odds of seeking formal versus informal healthcare for 
infants and children with fever <5 years of age with fever were 5.08 times greater than 
for individuals ≥12 years of age with fever (95% CI: 1.50, 17.1; p = 0.01; Table 2.7). For 
children 5 to 11 years of age with fever compared with individuals ≥12 years of age with 
fever, the odds ratio was 0.84 but the confidence interval also included values greater 
than one (95% CI: 0.32, 2.22; p = 0.72). We found no evidence of a difference in odds 
of seeking formal versus informal healthcare between female and male individuals with 
fever (OR = 1.09; 95% CI: 0.61, 1.97; p = 0.76).  
 
The odds of seeking formal versus informal healthcare by individuals with fever whose 
head of household’s education level was middle school were 0.29 (95% CI: 0.09, 0.89; 
p = 0.03) compared with individuals with fever whose head of household was primary 
school or less. Compared with individuals with fever whose head of household’s 
education level was primary school or less, the odds of seeking formal versus informal 
healthcare were 0.44 (95% CI: 0.13, 1.53; p = 0.19) for individuals whose head of 
household’s education level was high school. The odds of seeking formal versus 
informal healthcare for individuals with fever from Quintile 3, the middle wealth quintiles 
were 1.11 (95% CI: 0.31, 3.95, p = 0.86) times greater than for individuals from a 
household in Quintile 1, the poorest wealth quintile. For individuals from a household in 
Quintile 5, the richest quintile, compared with individuals in Quintile 1, the odds ratio was 




Table 2.7. Multivariable analysis of predictors of individuals with fever seeking 
formal healthcare versus seeking informal healthcare, survey of healthcare 
seeking behaviour and medicine use among individuals with fever in Yangon 




Multivariable analysis a 
Yes No OR (95% CI) p-value 
Age      
<5 years 






























Head of household education 
level b 
     
























Household wealth quintile c      






























a Adjusted for all other variables in the table. b Six individuals are missing a head of 
household education level as response was ‘unknown’. c One household is missing a 
wealth quintile as they were excluded from the principle component analysis due not 
providing any data on asset ownership.  
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2.3.7 Univariable analysis of predictors of seeking healthcare from a public 
versus private healthcare provider 
Exploration of which explanatory variables were associated with seeking healthcare at 
a public healthcare provider versus a private healthcare provider was limited by sample 
size; few respondents reported seeking healthcare at a public healthcare provider. 
Consequently, to fit a logistic regression model, I reduced certain categorical variables 
into binary variables. Categories were determined based on epidemiological 
considerations (e.g., comparing the healthcare seeking behaviours of adults compared 
to children). 
 
In our univariable analysis, the odds of seeking healthcare from a public versus private 
healthcare provider were 2.21 (95% CI: 0.69, 7.09; p = 0.18; Table 2.8) greater for 
infants and children <12 years of age with fever than for individuals ≥12 years of age 
with fever. The odds of seeking healthcare from a public versus private healthcare 
provider were 0.39 (95% CI: 0.09, 1.72; p = 0.21) for female compared with male 
individuals with fever. The odds of seeking healthcare from a public versus private 
healthcare provider were 1.56 (95% CI: 0.37, 6.52; p = 0.54) for individuals with fever 
whose head of household was employed compared with individuals with fever whose 
head of household was unemployed. 
 
The odds of seeking healthcare from a public versus private healthcare provider were 
0.36 (95% CI: 0.09, 1.42; p = 0.14) for individuals with fever whose head of household’s 
education level was middle school or greater compared with individuals with fever whose 
head of household’s education level was primary school or less. The odds of seeking 
healthcare from a public versus private healthcare provider were 0.82 (95% CI: 0.22, 
3.04; p = 0.76) for individuals with fever whose household weekly expenditure was 
≥K50,000 (US$37.40) compared with <K50,000 (<US$37.40). For individuals with fever 
from households in quintiles 3, 4, and 5 compared with individuals with fever from 
households in quintiles 1, and 2, the odds ratio for seeking healthcare from a public 
versus private healthcare provider was 0.27 (95% CI: 0.58, 1.28, p = 0.10). Numbers of 
individuals seeking formal healthcare were insufficient to conduct a multivariable 





Table 2.8. Univariable analysis of predictors of individuals with fever seeking 
formal healthcare from a public healthcare provider versus a private healthcare 
provider, survey of healthcare seeking behaviour and medicine use among 
individuals with fever in Yangon Region, Myanmar, 2018 (N = 174) 
Characteristics 
Healthcare Univariable analysis 
Public Private OR (95% CI) p-value 







































Head of household education level     
Primary school or less 











Household weekly expenditure       















Household wealth quintile       
Quintiles 1 and 2 











a MMK, Myanmar Kyat; US$, United States Dollar. 1.00 US$ = 1,337 MMK, 23 March 





2.3.8 Medicine use among individuals with fever 
Of the 237 individuals with fever included in our survey, 233 (98.3%; 95% CI: 95.7%, 
99.3%) used at least one type of medicine for fever treatment (Table 2.9). A total of 144 
(61.7%; 95% CI: 52.9%, 69.7%) individuals with fever used an analgesic; 105 (44.0%; 
95% CI: 35.5%, 52.8%) used an antibacterial; 1 (0.5%; 95% CI: 0.0%, 2.9%) used an 
antimalarial; 1 (0.5%; 95% CI: 0.0%, 3.4%) used an antituberculosis medicine; and 7 
(2.9%; 95% CI: 1.2, 7.1%) used a herbal medicine. Of seven individuals with fever who 
obtained herbal medicines, five (71.4%) obtained herbal medicines from a private 
primary care centre; one (14.3%) from a public hospital; and one (14.3%) from an 
informal healthcare provider.  
 
Table 2.9. Medicine use among individuals with fever, survey of healthcare 
seeking behaviour and medicine use among individuals with fever in Yangon 
Region, Myanmar, 2018 (N = 237) 
Medicines used for fever n  Proportion, (95% CI) a 





















Some individuals with fever used more than one type of medicine. a Proportions are 
percentages weighted to the Yangon Region population. 
 
2.3.9 Providers of antibacterial medicines to individuals with fever 
Of the 237 individuals with fever, 105 (44.0%, 95% CI: 35.5%, 52.8%) used an 
antibacterial. Of 105 antibacterials, 97 (92.7%; 95% CI: 84.7%, 96.7%) were obtained 
from a formal healthcare provider. A total of 86 (81.7%; 95% CI: 71.1%, 89.0%) of 105 
antibacterials were obtained from a private primary care centre; 8 (7.3%; 95% CI: 3.3%, 
15.3%) from an informal healthcare provider; 6 (6.2%; 95% CI: 2.9%, 12.9%) from a 
public hospital; 3 (2.6%; 95% CI: 0.8%, 8.0%) from a private hospital; and 2 (2.2%; 95% 




Table 2.10. Providers of antibacterials used by individuals with fever, survey of 
healthcare seeking behaviour and medicine use among individuals with fever in 
Yangon Region, Myanmar, 2018 (N = 237) 
Provider of antibacterials used for fever n  Proportion (95% CI) a 
Formal healthcare  
Public primary care centre 
Public hospital  





























a Proportions are percentages weighted to the Yangon Region population. 
 
2.4 Discussion 
2.4.1 Key findings 
To our knowledge, ours was the first survey of healthcare seeking behaviour and 
medicine use among individuals with fever in Yangon Region, Myanmar. We found that 
infants and children <5 years of age and children 5 to 11 years of age had greater odds 
of having fever versus not having fever compared with individuals ≥12 years of age. 
Younger age was the only characteristic that was found to be a statistically significant 
predictor of fever status in our survey.  
 
Approximately 73% (95%CI: 65.9%, 79.2%) of individuals with fever reported seeking 
formal healthcare, with the remainder seeking informal healthcare. Most individuals with 
fever who sought formal healthcare did so from a private primary care centre. No 
participants in our survey reported seeking healthcare for fever from a traditional 
medicine provider. We found that the odds of seeking formal versus informal healthcare 
were greater for infants and children <5 years of age with fever compared with older 
individuals with fever. We also found that the odds of an individual with fever seeking 
formal versus informal healthcare were greater when the head of household’s education 
level was primary school or less compared with each other education level. On 
univariable analysis, we did not find any individual or household characteristics that were 
associated with seeking healthcare from a public healthcare provider compared with a 
private healthcare provider. However, due to the small numbers of observations of some 
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characteristics we may have been limited in our ability to detect their effects on 
healthcare seeking behaviours and medicine use. 
 
We found that almost all individuals with fever obtained some type of medicine, and 
approximately 60.0% (95% CI: 52.9%, 69.7%) obtained an antibacterial. The most 
commonly reported provider of antibacterials to individuals with fever in our survey were 
private primary care centres, who provided 81.7% (95%CI: 71.1%, 89.0%) of 
antibacterials. Approximately 7.0% (95% CI: 3.3%, 15.3%) of antibacterials were 
provided by informal healthcare providers. 
 
2.4.2 Comparison with other studies 
Utilisation of alternative healthcare providers 
More than 70.0% of individuals with fever in our survey reported seeking formal 
healthcare, with the majority of these individuals seeking healthcare from a private 
healthcare provider. The high use of private healthcare providers in our survey was 
consistent with a recent study of healthcare seeking behaviours among individuals with 
drug-resistant tuberculosis in Yangon Region (43) but contrasted with findings from two 
previous surveys of healthcare seeking behaviours among individuals with fever in 
Myanmar (8,44). These findings suggest that healthcare utilisation in Yangon Region 
may differ from other areas of Myanmar. Yangon Region is the only predominantly urban 
administrative area in Myanmar (37), and the differences in healthcare seeking 
behaviour observed in our survey compared with previous surveys may reflect the 
greater availability and use of private healthcare providers in urban areas compared with 
rural areas (20,45).  
 
No participants reported seeking healthcare from a traditional medicine provider, 
although seven individuals with fever reported using an herbal medicine. Such low use 
of traditional medicine providers may reflect differences in healthcare preferences 
among urban populations compared with rural populations in Myanmar. Research 
suggests that in Myanmar individuals in a rural area are more likely to seek healthcare 
from a traditional medicine provider than individuals in an urban area (19,20). It is also 
possible that we underestimated the utilisation of traditional healthcare providers and 
the use of herbal medicines due to a reluctance of participants to share such information 
with the research team associated with a medical university (46).  
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That approximately a quarter of individuals with fever in our survey chose to seek 
informal healthcare is notable. This finding is similar to that from a 2015 study of 
treatment-seeking behaviour in malaria endemic regions of Myanmar which reported 
that 25.0% of participants that had experienced fever in the past two weeks did not use 
any medicines, or obtained medicines from an informal healthcare provider (44). Our 
finding is also consistent with the high out-of-pocket costs associated with seeking 
formal healthcare in Myanmar and the availability of medicines without a prescription 
(19,26,27). 
 
Predictors of seeking formal healthcare 
In our survey, we sought to ascertain which individual and household characteristics 
were associated with seeking formal healthcare compared with seeking informal 
healthcare. We found that infants and children <5 years of age with fever had greater 
odds of using formal healthcare versus informal healthcare compared with individuals 
with fever belonging to other age groups. We are aware of no other studies from South-
eastern Asia that specifically compared healthcare seeking behaviours for fever in 
infants and children <5 years of age with other age groups. However, our finding is 
consistent with infants and children <5 years of age being at high risk for fever compared 
with other age groups (47). Our finding is also consistent with studies of healthcare 
seeking for other health conditions that indicate that formal healthcare utilisation is 
generally higher in infants and children <5 years of age comapred to other age groups 
(48,49).  
 
We found that the odds of seeking formal healthcare compared with seeking informal 
healthcare did not differ between male and female individuals with fever in our survey. 
This was consistent with findings from the nationwide 2015-2016 Myanmar DHS  (8) and 
a survey of treatment-seeking behaviour for infants and children <5 years of age in 
Ayeyarwady Region (a region that neighbours Yangon Region that also has a Bamar 
ethnic majority) (37,50). However, our finding contrasts with a survey of healthcare 
seeking behaviour among individuals with fever in malaria-endemic areas of rural 
Myanmar (44) and a survey of healthcare seeking for fever among the Wa ethnic group 
in Shan Special Region II in northern Myanmar (45). Previous researcher has posited 
that cultural or social factors may influence the association between sex and healthcare 
seeking behaviours in Myanmar, however, more research is required to understand the 




We found weak evidence that the odds of seeking formal healthcare were higher for 
individuals with fever whose head of household’s education level was primary school or 
less compared with each higher level of education. In contrast, previous surveys that 
included details about education level, found that maternal or head of household 
education level had no effect on seeking formal healthcare for fever (8,45,50). We are 
aware of no clear explanation for why a head of household’s lower education level would 
increase the odds of seeking formal healthcare. 
 
We found no association between weekly expenditure or wealth quintile and the odds of 
seeking formal healthcare in our survey. This finding contrasted with previous surveys 
of healthcare seeking behaviour for fever in Myanmar that found seeking formal 
healthcare for fever to be associated with increasing wealth quintile, income, or 
socioeconomic status (8,44,45). Despite contrasting with these previous studies, our 
finding that there was no association between wealth and seeking formal healthcare 
may reflect an important difference in healthcare seeking in Yangon Region compared 
with other areas in Myanmar. The 2017 Myanmar Living Conditions Survey found that 
individuals in Yangon Region were generally relatively wealthier than individuals in other 
areas of Myanmar (53). Therefore, it is possible that the less wealthy households in our 
survey were wealthier relative to households in other areas of Myanmar and did not 
experience the same barriers to seeking formal healthcare. 
 
We did not ascertain details on the impact of illness severity, healthcare cost, healthcare 
quality, wait times, or distance to nearest healthcare provider on the likelihood of seeking 
formal healthcare in our survey. Previous studies in other LMICs suggest that these 
factors may each affect an individual’s ability to seek healthcare (54–58). However, we 
are aware of no empiric studies on the impacts that these factors have on healthcare 
seeking behaviours in Yangon Region.  
 
Based on our findings we recommend that interventions be developed to improve the 
availability and use of formal healthcare. We found that infants and children <12 years 
of age had greater odds of having fever versus not having fever compared with 
individuals ≥12 years of age. However, only infants and children <5 years of age with 
fever had greater odds of seeking formal healthcare. Consequently, we recommend that 
interventions be developed that emphasise the importance of seeking formal healthcare 
for children 5 to 11 years of age with fever. Further, we recommend that interventions to 
improve availability and use of formal healthcare also encourage cooperation between 




Medicine use  
We found that analgesics and antibacterials were commonly used by individuals with 
fever in our survey. Very few individuals with fever reported using antimalarials, 
antituberculosis medicines, or herbal medicines. Analgesics are often readily available 
as over-the-counter medicines and are used worldwide by individuals with fever to 
relieve pain and ease discomfort (59). Additionally, some analgesics, such as 
paracetamol and ibuprofen, have antipyretic properties that can be used to reduce the 
sometimes dangerous elevated body temperature associated with fever (59). 
 
Clinical management guidelines for fever often recommend that antibacterials be given 
to individuals if they are experiencing severe febrile illness, or the healthcare provider 
suspects or has confirmed that the cause of fever is bacterial (10,11). However, in 
Myanmar, antibacterials and other antimicrobials often prescribed to individuals with 
mild and self-limited infections and are readily available over-the-counter without a 
prescription (26,60). Our finding of widespread antibacterial use by individuals with fever 
in Yangon Region was consistent with previous research that showed antibacterials and 
other antimicrobials are readily available and commonly used by individuals with fever 
in other LMICs in South-eastern Asia (8,17).  
 
The unrestricted use of antibacterials by individuals with mild and self-limited infections 
has been shown to contribute importantly to the emergence and spread of AMR (61). 
The Myanmar National Action Plan on Prevention and Containment of Antimicrobial 
Resistance (60) acknowledges a lack of awareness about AMR in Myanmar and a 
substantial problem of inappropriate antimicrobial prescribing and over-the-counter 
antimicrobial sales. Consequently, the Myanmar MoHS has recently pledged to develop 
regulations and compliance checks for antimicrobial sales (60). 
 
We recommend that a dedicated community-based AMS programme be established in 
Yangon Region (62,63). A robust AMS programme based on local data with government 
support and multi-sectoral participation could substantially reduce the emergence and 
spread of AMR in the future (64,65).Our findings indicate that the inclusion of private 
primary care centres and informal healthcare providers, as the most common providers 
of antibacterials in Yangon Region, would be integral to an effective AMS programme. 
Interventions used in AMS programmes elsewhere may be beneficial in Yangon Region 
(62,64). Key AMS interventions may include surveillance of antimicrobial use and AMR; 
more robust regulation of antibacterial sales; increasing public awareness of AMR; and 
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providing education for healthcare providers, including informal healthcare providers, on 
the consequences of inappropriate antimicrobial use (64,66). 
 
2.4.3 Study strengths 
The major strengths of our survey were the selection of a representative sample, 
adjustment of analyses to reflect the total population of Yangon Region, and 
collaboration with local researchers and community health workers who planned the 
survey and conducted data collection. To our knowledge, our survey was the first survey 
of healthcare seeking behaviour and medicine use among individuals with fever in 
Yangon Region. The data collection process was straightforward and feasible in a low-
resource setting, and the similarity of our survey to other healthcare utilisation surveys 
enables meaningful comparisons to be made. The construction of a wealth index from 
survey response variables allowed us to consider long-term wealth as a predictor of 
healthcare seeking behaviours.  
 
2.4.4 Study limitations 
Our study had a number of limitations. First, as a secondary use of our survey data, the 
analyses presented here were not considered in the sample size estimation. 
Additionally, we did not include households from rural villages tracts. Thus, we were 
unable to compare healthcare seeking behaviour for urban households compared with 
rural households. If we assume that rural households are less likely to access formal 
healthcare providers, as has been found in previous studies of healthcare utilisation in 
Myanmar (67), the exclusion of rural households from our study may have biased our 
findings towards observing greater formal healthcare utilisation. Furthermore, 
terminology used in our survey may have been unfamiliar to some key informants, in 
turn leading to inaccurate responses (46). It is possible that these inaccurate responses 
may have led to an underestimation of healthcare seeking at certain healthcare 
providers and the use of certain medicines for fever. In addition, participants may have 
been reluctant to share some information with our interviewers, who were strangers 
associated with a large medical university. For example, participants may have been 
reluctant to report the use of traditional medicines leading to an underestimation of the 
use of traditional medicines for the treatment of fever. 
 
Second, we did not collect information about individuals who were unavailable or refused 
to participate in our study; non-participation may have biased our findings if individuals 
who were unavailable or refused to participate differed substantially from individuals that 
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agreed to participate. Individuals who agreed to participate may also have systematically 
under- or over-reported the use of certain healthcare providers and medicines to fit their 
impressions of correct healthcare utilisation and medicine use, or due to suboptimal 
recall of past actions (68). 
 
Third, we relied on ‘heads of households’ or ‘healthcare decision makers’ to function as 
key informants for all household members. As a consequence, we may not have 
captured all instances of healthcare utilisation and may have better captured information 
on more severe febrile illnesses and healthcare utilisation by the key informants 
themselves or younger dependent children. Furthermore, responses were dependent 
on key informants understanding the questions about healthcare utilisation and medicine 
use. Terminology used in our survey may have been uncommon and not confidently 
understood by our key informants, therefore potentially causing them to give untrue 
responses and thus underestimating our measurements of healthcare utilisation and 
medicine use for fever (46). In addition, participants may have been reluctant to share 
certain information with our interviewers, who were strangers associated with a large 
medical university. For example, participants may have been reluctant to report the use 
of traditional medicines leading to an underestimation of the use of traditional medicines 
for the treatment of fever.’ 
 
Fourth, at the time of questionnaire design, we did not anticipate informal healthcare 
providers being prominent sources of medicines. Consequently, we did not include 
detailed questions in our survey about seeking healthcare at informal healthcare 
providers. Our survey highlights that informal healthcare providers are potentially 
important providers of healthcare and medicines in Myanmar that should be considered 
in more detail in future surveys of healthcare seeking behaviours and medicine use. 
 
Fifth, we did not collect data on all important predictors of healthcare utilisation. Notably 
we did not collect information on the costs of healthcare utilisation and the distance to 
the nearest formal healthcare provider. Other studies have found that healthcare costs 
and the distance patients must travel in order to obtain healthcare are important 
predictors of healthcare utilisation (54,69,70). It has been suggested that this is 
especially true in LMICs where out-of-pocket healthcare user fees are high in relation to 
incomes, the density of healthcare providers is low, where the majority of patients are 
likely to travel to healthcare providers on foot, and where there are easily accessible 




Finally, there were some notable limitations in constructing my wealth index using PCA. 
Although the PCA method has been used, I recognise that PCA is not ideal for analysing 
binary data and my wealth index may have been improved by using an alternative 
method, such as multiple correspondence analysis (71). My wealth index also may have 
been improved by considering additional principal components, since the first principal 
component explained less than 20.0% of variation in asset ownership (71). I also 
acknowledge that we did not consider the number or value of each asset owned and did 
not collect data on some potential wealth indicators that are often used in the DHS (40). 
Although the assets included in our survey did not differ greatly from individuals 
recommended in the DHS manual, further work investigating the effects of using a 
different set of assets may be warranted (71). However, in spite of the potential 
limitations my construction of a wealth index did provide the ability to consider wealth as 
a predictor fever status and healthcare seeking for fever.  
 
2.4.5 Future research opportunities 
Our study highlights the importance of fever in Yangon Region and indicates that 
improvements may be made in the availability and use of formal healthcare and 
antibacterials. Future studies may seek to understand in more detail the factors that 
influence individuals with fever to seek healthcare from each alternative healthcare 
provider. Future studies may also explore the factors that influence healthcare providers 
to dispense various types of medicines, particularly antibacterials. In particular, 
researchers may seek to understand the motivations for healthcare providers in Yangon 
Region recommending antibacterials to individuals with mild febrile illnesses. Studies 
from others LMICs suggest that patient expectations, financial reward, pharmaceutical 
industry marketing, and inadequate knowledge appropriate antimicrobial use may each 
contribute importantly to antimicrobial prescribing decisions (72,73). To our knowledge, 
no research on this topic has been conducted in the Myanmar healthcare system. 
Understanding the common community sources of antibacterials, and other 
antimicrobials, will be important for planning effective AMS interventions to mitigate the 
emergence and spread of AMR in the community (64).  
 
2.4.6 Conclusions 
Our study adds to the limited data on healthcare seeking behaviour by individuals with 
fever in Myanmar specifically, and in other LMICs generally. We provide evidence that 
may be used by healthcare policy makers in Yangon Region to inform healthcare 
resource allocation and plan interventions to enhance healthcare seeking among 
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individuals with fever and promote prudent antimicrobial use in the community. We 
observed that infants and children <12 years of age were more likely to have had fever 
compared with individuals ≥12 years of age, and formal healthcare was most likely to be 
sought for infants and children <5 years of age. We further observed that private primary 
care centres were the most commonly utilised healthcare providers and were also major 
providers of antibacterials to individuals with fever. A moderate proportion of individuals 
with fever also reported seeking healthcare and obtaining antibacterials from informal 
healthcare providers. We propose that interventions aimed at improving access to 
affordable and acceptable formal healthcare; promoting greater awareness of AMR; and 
encouraging more prudent use of antibacterials in the community, have the potential to 
greatly improve the health of individuals in Yangon Region. Such interventions may be 
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3. Chapter 3 
Global Point-Prevalence Survey of 
Antimicrobial Consumption and 
Resistance at Yangon Children's Hospital, 




Antimicrobials are medicines that kill or stop the growth of microorganisms and are 
among the most commonly prescribed medicines worldwide (1,2). Antibacterials and 
other antimicrobials are vital for treating infections and for allowing safer childbirth, 
surgical procedures, organ transplants, and cancer chemotherapy (1). The 
microorganisms that antimicrobials target can evolve resistance, in turn compromising 
therapeutic capabilities; a phenomenon called antimicrobial resistance (AMR) (1). 
 
AMR is a major threat to global public health as it reduces the options for the effective 
treatment and prevention of many common infections in humans (1,3). Consequently, 
reducing the prevalence of AMR infections in humans is a priority of the World Health 
Organization (WHO), national governments, the pharmaceutical industry, and non-
government health organisations (2–6). Because of the high burden of infectious 
diseases and limited healthcare resources, reducing the emergence and spread of AMR 
in low- and middle-incomes (LMICs) is particularly important (2,7).  
 
In response to rising concerns around AMR, in 2015 the WHO released the Global 
Action Plan on Antimicrobial Resistance, one of the main objectives of which is to 
optimise the use of antimicrobials (8). As the benefits of antimicrobial use are optimised 
through appropriate antimicrobial prescribing, it is important that surveillance and 
research be conducted into antimicrobial prescribing practices (8). To date, surveillance 
and research into antimicrobial prescribing in LMICs, including in Myanmar, has been 




Broadly, antimicrobials can be classified as those prescribed either in the community 
setting, or in the hospital setting. No specific data on what proportion of antimicrobial 
prescribing occurs in each setting in Myanmar is available. However, studies of 
antimicrobial use in England and Denmark suggest that as much as 20.0% of 
antimicrobial use occurs in hospitals (11,12). Inappropriate antimicrobial prescribing in 
hospitals, including intensive and prolonged use of antimicrobials, paired with the 
presence of immunologically impaired patients, has been shown to be a driver of AMR 
infections that have the potential to spread within hospitals and into the community (13–
15). A higher proportion of antimicrobials prescribed in hospitals, compared with in the 
community, are administered by the parenteral route (16). The administration of 
antimicrobials via the parenteral route requires use of intravascular catheters increasing 
the likelihood of catheter-related bloodstream infections, an important type of hospital-
acquired infection(16). The Myanmar government has therefore identified surveillance 
of antimicrobial prescribing in hospitals as an important aspect of their strategic plan to 
contain AMR (10). 
 
The WHO recommends that all hospitals implement an antimicrobial stewardship (AMS) 
programme, defined as ‘an organisational or system-wide healthcare strategy to 
promote appropriate prescribing of antimicrobials through the implementation of 
evidence-based interventions’ (17). Effective AMS programmes have been shown to 
reduce the selective pressures that lead to the emergence and spread of AMR (18,19). 
The ultimate goal of any AMS programme is to encourage sustainable improvements in 
the appropriateness of antimicrobial prescribing (20). Thoroughly planned and 
judiciously implemented AMS programmes, especially those based on local 
antimicrobial prescribing data, have been shown to reduce inappropriate antimicrobial 
prescribing, hospital-acquired infections, length of hospital stays, and treatment 
duration(7,19,21,22). Such AMS programmes usually have a multidisciplinary AMS 
team, that may consist of infectious disease specialists, pharmacists, infection control 
nurses, and microbiologists, responsible for enacting a clear antimicrobial management 
strategy (19). Such a strategy usually involves continuously monitoring AMR and 
antimicrobial prescribing, and implementing interventions aimed at improving the 
appropriateness of antimicrobial prescribing (19).  
 
Data on paediatric antimicrobial prescribing in particular is limited and more information 
about the use of antimicrobials in paediatric populations is needed in order to provide 
better care (23,24). To our knowledge, no survey of antimicrobial consumption and 
resistance has been conducted using the Global-PPS method at a paediatric hospital in 
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Myanmar or any other LMIC in South-eastern Asia. Data on the extent and quality of 
antimicrobial prescribing is necessary for planning and implementing an effective AMS 
programme (19). Point-prevalence surveys (PPS) are a proven way of relatively easily 
and inexpensively collecting antimicrobial prescribing data (20,25). Once collected, data 
on the most commonly prescribed antimicrobials, the reasons for antimicrobial use, and 
various quality indicators of antimicrobial prescribing can inform the suitability of various 
AMS interventions (20,21). Ongoing monitoring of antimicrobial prescribing through 
subsequent PPS can also be useful for measuring the impacts of any AMS interventions 
over time (19,26).  
 
3.1.2 Objective 
As data on hospital-based paediatric antimicrobial prescribing in Myanmar are scarce, 
we planned a PPS of antimicrobial prescribing at Yangon Children’s Hospital (YCH), 
Yangon, Myanmar. We sought to describe antimicrobial prescribing at YCH and assess 
agreement with various quality indicators of antimicrobial prescribing. The data 
generated in our study may serve as a baseline for future surveys of antimicrobial 
prescribing in Myanmar, as well as provide data useful for the development of evidence-
based AMS activities at YCH and other Myanmar hospitals.  
 
3.2 Methods 
3.2.1 Study design 
We conducted a PPS of antimicrobial consumption and resistance at YCH, Yangon, 
Myanmar, using the standardised and validated Global Point-Prevalence Survey of 
Antimicrobial Consumption and Resistance (Global-PPS) method (27). This method was 
developed by the Global-PPS development group and is supported by the Global-PPS 
Coordination Centre at the University of Antwerp, Belgium. The Global-PPS builds upon 
the experience of three PPS carried out by the European Surveillance of Antimicrobial 
Consumption (ESAC) project from 2006 through 2009 (27). Launched in 2014, and open 
to any hospital or research group in the world, the Global-PPS aims to describe 
antimicrobial consumption and resistance in hospitals and create global awareness 
about the use of antimicrobials and the growing threat of AMR. Data collected using this 
method are intended to aid in the development of evidence-based AMS policies in 




3.2.2 Study setting 
The setting for our PPS was YCH, a 750-bed public tertiary referral hospital in Yangon, 
Myanmar (29). YCH admits children aged 0-14 years and is the main referral children’s 
hospital for the Yangon Region and Lower Myanmar. However, patients can also be 
referred from elsewhere in the country (30,31). YCH houses neonatal and paediatric 
medical and surgical inpatient wards, intensive care units, outpatient clinics, and an 
emergency department (30). Inpatient services include general paediatric medicine, 
general paediatric surgery, haematology-oncology, intensive care, neonatology, 
nephrology, neurology, paediatric orthopaedic surgery (30). Treatment at YCH, as with 
other public hospitals in Myanmar, is nominally free at the point of care. However, 
patients’ families are often required to pay out-of-pocket for some of the consultation, 
medicine, and food costs (32). 
 
YCH was chosen as the setting for our PPS through an established collaborative 
programme of research, training, and service between the University of Otago, 
University of Medicine 1, Yangon, and University of Public Health, Yangon. Participation 
of the hospital was voluntary and permission to conduct this study was given by 
Myanmar’s Minister of Health and Sport, and the Director of YCH.  
 
3.2.3 Study population 
Our study population included all inpatients present on each ward of YCH at 08:00AM 
on the day of data collection. All inpatients admitted on a surveyed ward were counted 
for the ward survey and all those prescribed at least one antimicrobial were counted for 
the patient survey. 
 
3.2.4 Sample size justification 
YCH is a 750-bed public tertiary hospital for children, which in 2013 had an average 
occupancy of 64% (29). Assuming the same occupancy percentage at the time of our 
survey, we expect to include 480 participants in our survey. Assuming that 50% of 
participants are prescribed at least one antimicrobial, our margin of error will be 
approximately 5%. We expect that the true proportion will be close to 50% based on the 
findings of the 2015 Global-PPS which found that the mean antimicrobial prescribing 




3.2.5 Ward selection 
Each ward was surveyed on a single day selected by senior clinical staff on that ward. 
Senior clinical staff on each ward selected one day from 9 December 2019 through 21 
December 2019 that was convenient for their ward to be surveyed and complied with a 
set of pre-specified parameters. We did not survey any wards on the weekends (i.e., 
Saturday and Sunday), following the Global-PPS assumption that fewer patients would 
be admitted on weekends compared with weekdays. We surveyed medical wards and 
intensive care units on any weekday (i.e. Monday through Friday) but did not survey 
surgical wards on a Monday or a public holiday. This restriction on when surgical wards 
were surveyed was to reflect the Global-PPS assumption that fewer elective surgeries 
would be performed on the weekends and public holidays, and to ensure that we could 
accurately capture the duration of antimicrobial use for surgical prophylaxis (e.g., if 
surgical prophylaxis was continued after surgery, and if so, for how long) (27).  
 
3.2.6 Inclusion criteria for patient survey 
The medical records of all inpatients on the ward at 08:00AM were reviewed to 
determine those receiving at least one antimicrobial. Antimicrobials of interest included 
antibacterials for systemic use; antimycotics and antifungals for systemic use; drugs for 
treatment of tuberculosis; antimicrobials used as intestinal anti-infectives; antiprotozoals 
used as antibacterial agents; nitroimidazole derivatives; antivirals for systemic use; and 
antimalarials (27). Consistent with Global-PPS methods. long-acting antimicrobials and 
intermittent treatment on alternative days were included if given within the 24 hours 
immediately preceding the survey but topical antimicrobials were not of interest and data 
on their use were not recorded (27).  
 
3.2.7 Exclusion criteria for patient survey 
As specified in the Global-PPS protocol (27), day hospitalisations, ambulatory care 
patients, and patients ready for discharge who were awaiting transport were excluded 
from our study. These exclusion criteria ensured that study resources were used 
economically, and that data collected related only to antimicrobial consumption 
associated with care received in the inpatient hospital setting. 
 
3.2.8 Survey instrument  
We utilised the Global-PPS standardised paper data collection forms to collect data 
about antimicrobial consumption and resistance at YCH (Appendix 3). One ward data 
collection form was completed for each surveyed ward. The ward data collection form 
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contained fields for the date of the survey; auditor name; hospital name; ward name; 
department type; healthcare activities (i.e., medical, surgical, or intensive care) 
encountered on the ward; and total number of available beds and admitted patients by 
healthcare activity. One patient data collection form was completed for each patient 
meeting the eligibility criteria for the patient survey. The patient data collection form 
contained fields for the ward name; patient healthcare activity; a unique patient identifier 
and survey number; age; weight; gender (i.e., biological sex); and details of each 
antimicrobial prescribed. Antimicrobial prescribing details sought included the generic 
antimicrobial name; the dose, frequency, and route of antimicrobial administration; a 
diagnosis code; a treatment indication code; whether the reason for antimicrobial use 
and a stop or review date was recorded in the medical record; whether treatment choice 
was based on a biomarker result (i.e. C-reactive protein or procalcitonin test result) or a 
microbiology laboratory test result; and whether the antimicrobial prescribed was 
compliant with local treatment guidelines. 
 
Most data could be directly transcribed from the patients’ medical records. However, 
specific diagnosis codes, treatment indication codes, and guideline compliance 
assessments were not included in the medical records as these are unique components 
of the Global-PPS method (Appendix 4). Diagnosis codes were grouped by anatomical 
site and broadly characterised the site of infection and the diagnosis that clinicians 
aimed to prevent or treat. For example, diagnosis codes for the gastrointestinal tract 
included ‘gastrointestinal prophylaxis, including prophylaxis for abdominal surgeries, 
neutropenia, or hepatic failure,’ ‘gastrointestinal treatment, including treatments for 
gastrointestinal infections such as Campylobacter and Clostridioides difficile’, and ‘intra-
abdominal treatment, including treatments for intra-abdominal sepsis, and intra-
abdominal abscesses.’ Treatment indication codes were grouped into four types: 
community-acquired infection (CAI), hospital-acquired infection (HAI), medical 
prophylaxis (MP), and surgical prophylaxis (SP). Infections were considered to be CAIs 
if symptoms were present on admission or started <48 hours after admission and HAIs 
if symptoms started ≥48 hours after admission (27). Prophylaxis was considered medical 
prophylaxis if it was to prevent infections in patients with medical conditions, and was 
considered surgical prophylaxis if it was to prevent surgical site infections in patients 
undergoing surgery (27). Surgical prophylaxis was grouped into three types based on 
duration (single dose, ≤1 day, >1 day) of antimicrobial use. These groups were informed 
by international guidelines that recommend surgical prophylaxis consist of a single dose 
of a narrow-spectrum antimicrobial administered within the 24-hour preoperative period, 




3.2.9 Staff selection and training 
Based on the literature and investigators’ previous experiences of conducting hospital-
based studies, we employed 15 junior doctors to serve as data collectors for this survey 
(37). Junior doctors were chosen based on their availability and their familiarity with the 
hospital facilities, staff, and medical terminology. We also employed three senior medical 
students to assist with data entry.  
 
I led a one-day training session to ensure that data collectors understood the objectives 
and processes of the Global-PPS. During the training session I delivered a presentation 
and answered questions from the survey team about the survey protocol. I also oversaw 
practical exercises in which the data collectors became familiar with the data collection 
forms, and practised data collection. All data collectors were required to attend the 
training session as a condition of their employment. The data entry team also attended 
the training session and received additional on-the-job training on how to review data 
collection forms for logic and completeness, assess guideline compliance, and enter 
data into the online Global-PPS database. 
 
3.2.10 Data collection 
Drs Win Thandar Oo (Assistant Lecturer, Department of Microbiology, University 
Medicine 1, Yangon and PhD student, Centre for International Health, University of 
Otago, Dunedin) and Khine Mar Oo (Lecturer, Department of Microbiology, University 
Medicine 1, Yangon) supervised data collection at YCH. Prof John A. Crump, Dr 
Christian S. Marchello, and I were based at University of Medicine 1, Yangon, with the 
data entry team, and as foreign nationals were not permitted on the hospital wards. 
 
Dr Win Thandar Oo completed the ward data collection form for each surveyed ward, 
and the data collectors completed a patient data collection form for each patient meeting 
the inclusion criteria for the patient survey. If variables on the patient data collection form 
could not be ascertained from the medical record, data collectors consulted the clinical 
ward staff for clarification. No opinions about the appropriateness, or lack thereof, of 
antimicrobial prescribing were voiced by members of the research team to the clinical 
ward staff. In addition, no contact was made between members of the research team 




3.2.11 Data verification 
On the first day of data collection, Dr Marchello and I reviewed each patient data 
collection form for completeness, logic, and accuracy. First, we identified if any expected 
data were missing. Second, we reviewed antimicrobial prescription details, diagnosis 
codes, and treatment indication codes based on expected combinations as laid out in 
the Global-PPS protocol (27). For example, an antimicrobial for which there is no oral 
formulation should have been given by another route of administration, and an 
antimicrobial prescription which had a prophylactic diagnosis code should also have had 
a prophylactic treatment indication code (e.g., a prescription with the diagnosis code of 
gastrointestinal prophylaxis should have a treatment indication code of medical 
prophylaxis or surgical prophylaxis). Third, we audited the reporting of guideline 
compliance against the Myanmar Pediatric Society’s ‘Pediatric Management Guidelines’ 
(38). In the event that we encountered a high proportion of missing data, logical errors, 
or accuracy concerns, I planned to conduct further training of the data collectors and to 
train the data entry team to perform thorough data verification before data entry. Dr 
Marchello and I planned to jointly supervise data verification. 
 
3.2.12 Assessment of guideline compliance 
We requested local antimicrobial prescribing guidelines from the hospital administration 
at YCH while preparing the ethics application for this PPS. We were informed that such 
guidelines did not exist; a position reiterated over the course of planning the PPS. 
Consequently, we planned to conduct the PPS without assessing guideline compliance. 
However, upon arrival in Myanmar to conduct the PPS, it became apparent that a set of 
guidelines was widely used within the hospital and two days prior to data collection 
began we were provided with a copy of the third edition of the Myanmar Pediatric 
Society’s ‘Pediatric Management Guidelines’ (38). Upon receiving the guidelines, we 
adjusted the data collection and validation processes accordingly in order to 
accommodate the assessment of guideline compliance. 
 
Assessments of guideline compliance were dependent on the diagnosis being identified 
and a guideline being available for that diagnosis. Where there was a guideline for a 
specific diagnosis, a prescription was classified as either ‘guideline compliant’ or ‘not 
guideline compliant.’ Consistent with Global-PPS methods, if an antimicrobial was given 
in combination with an enzyme inhibitor but the guideline did not specify the use of an 
enzyme inhibitor, or if an antimicrobial was not given in combination with an enzyme 
inhibitor when the guideline specified such a combination, we recorded the prescription 
as ‘not guideline compliant.’ If an antimicrobial was prescribed on the direct advice of a 
125 
 
specialist infectious disease physician, it was deemed to be ‘guideline compliant’ 
regardless of the written guidelines (27). If no guideline existed for a specific diagnosis, 
or no diagnosis could be determined for a given prescription, guideline compliance could 
not be assessed and we recorded guideline compliance as ‘no guideline available’ or 
‘diagnosis unknown,’ respectively. In accordance with the Global-PPS protocol (27), we 
assessed only if the chosen antimicrobial was compliant with the guidelines, and did not 
assess the compliance of dose, frequency, route of administration, or duration of 
antimicrobial treatment. 
 
Consistent with the Global-PPS protocol, data collectors recorded whether each 
antimicrobial prescription was compliant with guidelines or not. In the event that we 
became concerned about the accuracy of the assessment of guideline compliance 
during data verification, we had data collectors instead record the diagnosis for which 
each antimicrobial was prescribed on the patient data collection forms. We revisited the 
medical records for those patients where the data collected were deemed to be 
inadequate. I then planned to subsequently assess guideline compliance for all 
antimicrobial prescriptions using an electronically searchable copy of the ‘Pediatric 
Management Guidelines’, with the assistance of Dr Christian S. Marchello and the data 
entry team.  
 
3.2.13 Data entry and validation 
We had initially planned to enter data directly from the paper data collection forms into 
the online Global-PPS database. However, this was not possible due to technical issues 
with the database beginning 6 December 2019 (personal communication with Ann 
Verstappen, Global-PPS Coordination Centre, 6 December 2019). We then planned to 
enter all data into a structured Microsoft Excel spreadsheet (Microsoft, Redmond, WA, 
USA) supplied by the Global-PPS Coordination Centre, and automatically import the 
data into the online database when fixed. However, due to ongoing technical issues with 
the online database, we instead shared the structured Excel spreadsheet with the 
Global-PPS Coordination Centre who had one staff member manually enter the data. I 
then exported data from the online database in an Excel spreadsheet and cross-
referenced data entry against the original data file. 
 
Upon entry into the online database, each patient was given a unique survey number 
and each antimicrobial was classified using the WHO’s Anatomical Therapeutic 
Chemical (ATC) classification system (39). Each ward was also classified as belonging 
to one of six department types: paediatric medical wards (PMW), paediatric 
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haematology-oncology wards (PMW-HO), paediatric surgical wards (PSW), paediatric 
intensive care units (PICU), neonatal medical wards (NMW), or neonatal intensive care 
units (NICU). Automated validation of data was also completed by the online database, 
further ensuring that data were logically coherent (27). 
 
3.2.14 Statistical analysis 
I exported the complete validated survey data from the online database and analysed it 
using Stata, version 16.0 (StataCorp LLC, College Station, TX, USA). I calculated the 
proportion of patients prescribed at least one antimicrobial and determined the 
proportion of antimicrobials prescribed for each department type, diagnosis code, and 
treatment indication (including the duration of surgical prophylaxis). I determined the 10 
most commonly prescribed antimicrobials overall, for therapeutic use, and for 
prophylactic use. I also described therapeutic and prophylactic antimicrobial 
prescriptions by site of infection.  
 
I performed analyses to describe various quality indicators of antimicrobial prescribing, 
including determining compliance with antimicrobial prescribing guidelines, the route of 
antimicrobial administration, whether a reason for antimicrobial use and a stop or review 
date was recorded in the medical record, and whether antimicrobial prescribing was 
informed by a biomarker or microbiology test result. I analysed antimicrobial 
prescriptions (and not individual patients) as individuals could be prescribed multiple 
antimicrobials for one or more different diagnoses. 
 
3.2.15 Research ethics 
Ethics approval for the project was obtained from the University of Public Health 
Institutional Review Board, Yangon, Myanmar; and the University of Otago Human 
Ethics Committee (Health), Dunedin, New Zealand. Consistent with Global-PPS norms, 
since members of the data collection team did not interact with patients, and the project 
served an audit function, consent was not sought from each individual patient. Instead, 
authorisation for the project was obtained from the lead hospital administrator and the 
physicians in charge of each surveyed ward. We collected only deidentified patient data, 
and data collection forms and electronic data were only accessible to study 





We conducted data collection for the Global-PPS at YCH from 9 December 2019 
through 21 December 2019. We surveyed all thirteen wards at YCH: five PMW, one 
PMW-HO, three PSW, PICU, one NMW, and one NICU. PMW comprised three general 
medical wards, one renal ward, and one neurology ward, and PSW comprised two 
general surgical wards and one orthopaedic surgery ward.  
 
Early in the data collection process, we found that many forms had missing data, logical 
errors, or raised concerns about the accuracy of the assessment of guideline 
compliance. Consequently, I conducted further training of the data collectors and had 
them record the diagnosis for which each antimicrobial was prescribed on the patient 
data collection forms. I assessed guideline compliance for all antimicrobial prescriptions 
with the assistance of Dr Christian S. Marchello and the data entry team.  
 
3.3.1 Occupancy and prevalence of antimicrobial use by department type 
Across all surveyed wards there were 752 available beds, of which 507 (67.4%) were 
occupied by patients. Occupancy ranged from 13 (23.6%) of 55 beds in NMW to 63 
(81.8%) of 77 beds and 213 (81.9%) of 260 beds in PMW-HO and PSW, respectively. 
Of the 507 admitted patients, 306 (60.4%) were prescribed at least one antimicrobial. A 
total of 506 antimicrobials were prescribed to the 306 patients, median of one (range 1-
10) antimicrobial per patient. The proportion of patients who were prescribed at least 
one antimicrobial by department type ranged from 25 (39.7%) of 63 patients on the 




Table 3.1. Occupancy and prevalence of antimicrobial use by department type, 
Global Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 



















 n        (%) n        (%) % n        (%) % 
All wards 752 (100.0) 507 (100.0) 67.4 306 (100.0) 60.4 
PMW 323   (43.0) 195   (38.5) 60.4 80   (26.1) 41.0 
PMW-HO 77   (10.2) 63   (12.4) 81.8 25     (8.2) 39.7 
PSW 260   (34.6) 213   (42.0) 81.9 173   (56.5) 81.2 
PICU 22     (2.9) 13     (2.6) 59.1 11     (3.6) 84.6 
NWM 55     (7.3) 13     (2.6) 23.6 13     (4.2) 100.0 
NICU 15     (2.0) 10     (2.0) 66.7 4     (1.3) 40.0 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 
Neonatal Medical Ward; NICU, Neonatal Intensive Care Unit. 
 
3.3.2 Characteristics of patients prescribed at least one antimicrobial 
Of the 306 patients who were prescribed at least one antimicrobial, 40 (13.1%) were 
aged 1-30 days, 86 (28.1%) were aged 1-23 months, and 180 (58.8%) were aged 2-14 
years. Of 306 patients, 111 (36.3%) were female. A total of 185 (60.5%) patients were 
prescribed one antimicrobial, 76 (24.8%) were prescribed two antimicrobials, and 45 
(14.7%) were prescribed three or more antimicrobials. Of 306 patients, 222 (72.5%) 
received at least one antimicrobial prescription informed by a biomarker result, and 15 





Table 3.2. Characteristics of 306 patients who were prescribed at least one 
antimicrobial, Global Point-Prevalence Survey of Antimicrobial Consumption and 
Resistance at Yangon Children's Hospital, Yangon, Myanmar, December 2019 
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* No demographic or prescribing information were collected for individuals not 
prescribed at least one antimicrobial. 
 
3.3.3 Summary of all antimicrobial prescriptions 
Classification of antimicrobials prescribed at Yangon Children’s Hospital 
A total of 506 antimicrobials were prescribed to 306 patients during the GPPS at YCH. 
Classified by ATC therapeutic subgroups, antibacterials for systemic use accounted for 
406 (80.2%); antimycobacterials for 41 (8.1%); antiprotozoals for 36 (7.1%); 
antidiarrheals, intestinal anti-inflammatories, or anti-infectives for 14 (2.8%); antivirals 
for systemic use for 5 (1.0%); and antimycotics for systemic use for 4 (0.8%) of 506 
antimicrobial prescriptions (Table 3.3). By antimicrobial class, third-generation 
cephalosporins and combinations of penicillins accounted for 189 (37.4%) and 61 




Table 3.3. Classification of prescribed antimicrobials, Global Point-Prevalence 
Survey of Antimicrobial Consumption and Resistance at Yangon Children's 
Hospital, Yangon, Myanmar, December 2019 (N = 506) 
Antimicrobial classification  n       (%)     
Antibacterials for systemic use 406   (80.2) 
Third-generation cephalosporins 189   (37.4) 
Combinations of penicillins a 61   (12.1) 
Aminoglycosides other than streptomycins b 44     (8.7) 
Penicillins with extended-spectrum c 29     (5.7) 
Imidazole derivatives 19     (3.8) 
Sulfonamide and trimethoprim combinations 15     (3.0) 
Carbapenems 13     (2.6) 
Beta-lactamase sensitive penicillins 9     (1.8) 
Fluoroquinolones 9     (1.8) 
Glycopeptide antibacterials 9     (1.8) 
Macrolides 5     (1.0) 
Beta-lactamase resistant penicillins 2     (0.4) 
Fourth-generation cephalosporins 2     (0.4) 
Antimycobacterials 41     (8.1) 
Antibiotics for treatment of tuberculosis 41     (8.1) 
Antiprotozoals 36     (7.1) 
Nitroimidazole derivatives 31     (6.1) 
Aminoquinolines 4     (0.8) 
Artemisinin and derivatives 1     (0.2) 
Antidiarrheals, intestinal anti-inflammatories, or anti-infectives 14     (2.8) 
Antibiotics 14     (2.8) 
Antivirals for systemic use 5     (1.0) 
Nucleosides and nucleotides 5     (1.0) 
Antimycotics for systemic use 4     (0.8) 
Triazole derivatives 4     (0.8) 
Antimicrobials classified based on Anatomical Therapeutic Chemical (ATC) 
classification system therapeutic subgroup and antimicrobial class, ordered by 
prescription frequency. a Combinations of penicillins includes combinations of two or 
more penicillins, and penicillin and enzyme inhibitor combinations. b Aminoglycosides 
other than streptomycins includes gentamicin, neomycin, and amikacin. c Penicillins with 




3.3.4 Antibacterial prescriptions  
Antibacterial prescriptions by treatment indication 
Of the 406 antibacterials prescribed, 199 (49.0%) were for therapeutic use, 202 (49.7%) 
were for prophylactic use, and 5 (1.2%) were for an unknown or other use. A total of 176 
(43.3%) of 406 antibacterial prescriptions were for CAI, 23 (5.7%) were for HAI, 66 
(16.3%) were for MP, and 136 (33.5%) were for SP (Table 3.4). Of the 136 antibacterials 
prescribed for SP, 6 (4.4%) were given as a single dose, 25 (18.4%) were given for a 
duration ≤1 day, and 105 (77.2%) were given for a duration >1 day (Figure 3.1).  
 
Table 3.4. Antibacterial prescriptions by treatment indication, Global Point-
Prevalence Survey of Antimicrobial Consumption and Resistance at Yangon 
Children's Hospital, 2019 (N = 406) 
Treatment indication n       (%) 
Therapeutic use 199   (49.0) 
Community-acquired infections 
Hospital-acquired infections 
176   (43.3) 
23     (5.7) 
Prophylactic use 202   (49.7) 
Medical Prophylaxis 
Surgical Prophylaxis  
66   (16.3) 
136   (33.5) 




Figure 3.1. Duration of antibacterial use for surgical prophylaxis, Global Point-
Prevalence Survey of Antimicrobial Consumption and Resistance at Yangon 
Children's Hospital, Yangon, Myanmar, December 2019 (N = 136)  
0 20 40 60 80 100
Proportion of surgical prophylaxis (%)
Single dose Duration ≤ 1 day Duration > 1 day
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Most commonly prescribed antibacterial classes by treatment indication 
Third-generation cephalosporins were the most common class of antibacterials 
prescribed for therapeutic use and prophylactic use, accounting for 81 (40.7%) of 199 
prescriptions and 106 (52.5%) of 202 prescriptions, respectively. Combined, third-
generation cephalosporins and combinations of penicillins accounted for 121 (60.8%) of 
199 prescriptions for therapeutic use (Table 3.5). 
 
Table 3.5. Most commonly prescribed antibacterial classes by treatment 
indication, Global Point-Prevalence Survey of Antimicrobial Consumption and 
Resistance at Yangon Children's Hospital, 2019 (N = 401) 
Therapeutic use a  
(N = 199) 
Prophylactic use a  
(N = 202) 








Combinations of penicillins b 40 (20.1) Combinations of penicillins b 21 (10.4) 
Aminoglycosides other than 
streptomycins c 
23 (11.6) 





17   (8.5) Imidazole derivatives 14   (6.9) 
Carbapenems 8   (4.0) 
Sulfonamide and 
trimethoprim combinations 
12   (5.9) 
Fluoroquinolones 6   (3.0) 
Penicillins with extended-
spectrum d 
10   (5.0) 
Glycopeptide antibacterials 6   (3.0) Carbapenems 5   (2.5) 
Beta-lactamase sensitive 
penicillins 
5   (2.5) 
Beta-lactamase sensitive 
penicillins 
4   (2.0) 
Imidazole derivatives 5   (2.5) Fluoroquinolones 3   (1.5) 
Macrolides 4   (2.0) Glycopeptide antibacterials 3   (1.5) 
Antibacterials above the dashed line cumulatively accounted for 50.0% of prescriptions 
for each treatment indication. a Therapeutic use includes antibacterials prescribed for 
CAI and HAI. Prophylactic use includes antibacterials prescribed for MP and SP. Five 
antibacterial prescriptions were for an unknown or other use; these are not included in 
the table. b Combinations of penicillins includes combinations of two or more penicillins, 
and penicillin and enzyme inhibitor combinations. c Aminoglycosides other than 
streptomycins includes gentamicin, neomycin, and amikacin. d Penicillins with extended-
spectrum includes ampicillin, amoxicillin, and piperacillin.  
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Most commonly prescribed antibacterials by treatment indication 
Overall, there were 28 different antibacterials for systemic use, including combinations, 
prescribed. Cefotaxime was the most commonly prescribed antibacterial for therapeutic 
use accounting for 31 (15.6%) of 199 prescriptions. Ceftriaxone was the most commonly 
prescribed antibacterial for prophylactic use accounting for 77 (38.1%) of 202 
prescriptions. Five and three antibacterials accounted for 50.0% of antibacterial 
prescriptions for therapeutic use and prophylactic use, respectively (Table 3.6). 
 
Table 3.6. Most commonly prescribed antibacterials for each treatment indication, 
Global Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 
Yangon Children's Hospital, 2019 (N = 401) 
Therapeutic use a  
(N = 199) 
Prophylactic use a  
(N = 202) 
Antimicrobial n     (%) Antimicrobial n     (%) 
Cefotaxime 31 (15.6) Ceftriaxone 77 (38.1) 
Ceftriaxone 24 (12.1) Cefixime 14   (6.9) 
Combinations of penicillins b 20 (10.1) Cefotaxime 14   (6.9) 
Amoxicillin and enzyme 
inhibitor 
15   (7.5) Metronidazole 14   (6.9) 
Amikacin 12   (6.0) Amikacin 13   (6.4) 
Cefixime 12   (6.0) Combinations of penicillins b 12   (5.9) 
Gentamicin 11   (5.5) Trimethoprim-
sulfamethoxazole 
12   (5.9) 
Amoxicillin 9   (4.5) Gentamicin 6   (3.0) 
Piperacillin and enzyme 
inhibitor 
7   (3.5) 
Piperacillin and enzyme 
inhibitor 
6   (3.0) 
Ampicillin 6   (3.0) Amoxicillin 5   (2.5) 
Vancomycin 6   (3.0) Meropenem 5   (2.5) 
Antibacterials above the dashed line cumulatively accounted for 50.0% of prescriptions 
for each treatment indication. a Therapeutic use includes antibacterials prescribed for 
community-acquired infections and hospital-acquired infections. Prophylactic use 
includes antibacterials prescribed for medical prophylaxis and surgical prophylaxis. Five 
antibacterial prescriptions were for an unknown or other use; these are not included in 
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the table. b Combinations of penicillins includes combinations of two or more penicillins, 
and penicillin and enzyme inhibitor combinations.  
 
Antibacterial prescriptions by diagnosis 
The ten most common diagnoses for which antibacterials were prescribed accounted 
for 346 (85.2%) of 406 antibacterial prescriptions. The most common diagnosis was 
gastrointestinal tract prophylaxis for which 89 (21.9%) of 406 antibacterials were 
prescribed. Pneumonia was  the most common therapeutic diagnosis and the third most 
common diagnosis for which antibacterials were prescribed overall, accounting for 46 
(11.3%) of 406 antibacterial prescriptions (Table 3.7).  
 
Table 3.7. Most common diagnoses for which antibacterials were prescribed, 
Global Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 
Yangon Children's Hospital, 2019 (N = 406) 
Diagnosis n     (%) 
Gastrointestinal tract prophylaxis 89 (21.9) 
Skin, soft tissue, bone, or joint prophylaxis 50 (12.3) 
Pneumonia 46 (11.3) 
Neutropenic fever 43 (10.6) 
Skin and soft tissues infections 36   (8.9) 
Sepsis 26   (6.4) 
Gastrointestinal tract infection 17   (4.2) 
Bone and joint infection 12   (3.0) 
Central nervous system infection 11   (2.7) 
Pyelonephritis 9   (2.2) 




3.3.5 Key quality indicators of antimicrobial prescribing 
Guideline compliance 
Of 506 antimicrobial prescriptions across all wards, a guideline was available for 279 
(55.1%), no guideline was available for 224 (44.3%), and the diagnosis was unknown 
for three (0.6%). The availability of guidelines for diagnoses encountered on a specific 
ward ranged from 51 (20.6%) of 248 antimicrobial prescriptions on the PSW to 33 
(94.3%) of 35 antimicrobial prescriptions on the NMW, 48 (96.0%) of 50 antimicrobial 
prescriptions on the PMW-HO, and 128 (96.2%) of 133 antimicrobial prescriptions on 
the PMW (Table 3.8). 
 
Table 3.8. Guideline availability for antimicrobials prescribed by department type, 
Global Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 
Yangon Children's Hospital, Yangon, Myanmar, December 2019 (N = 506) 









All wards, n (%) 279   (55.1) 224   (44.3) 3     (0.6) 506 (100.0) 
PMW, n (%) 128   (96.2) 4     (3.0) 1     (0.8) 133 (100.0) 
PMW-HO, n (%) 48   (96.0) 2     (4.0) 0     (0.0) 50 (100.0) 
PSW, n (%) 51   (20.6) 195   (78.6) 2     (0.8) 248 (100.0) 
PICU, n (%) 9   (33.3) 18   (66.7) 0     (0.0) 27 (100.0) 
NMW, n (%) 33   (94.3) 2     (5.7) 0     (0.0) 35 (100.0) 
NICU, n (%) 10   (76.9) 3   (23.1) 0     (0.0) 13 (100.0) 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 




Guideline compliance of antimicrobials prescribed for a diagnosis for which a 
guideline was available 
Of antimicrobial prescriptions for a diagnosis for which a guideline was available, 218 
(78.1%) of 279 antimicrobial prescriptions were guideline compliant (Table 3.9). Of 128 
assessable prescriptions in the PMW, 113 (88.3%) were guideline compliant. Of 48 
assessable prescriptions in the PMW-HO, 26 (54.2%) of 48 were guideline compliant.  
 
Table 3.9. Guideline compliance of antimicrobials prescribed for a diagnosis for 
which a guideline was available, by department type, Global Point-Prevalence 
Survey of Antimicrobial Consumption and Resistance at Yangon Children's 








All wards, n (%) 218   (78.1) 61   (21.9) 279   (100.0) 
PMW, n (%) 113   (88.3) 15   (11.7) 128   (100.0) 
PMW-HO, n (%) 26   (54.2) 22   (45.8) 48   (100.0) 
PSW, n (%) 41   (80.4) 10   (19.6) 51   (100.0) 
PICU, n (%) 6   (66.7) 3   (33.3) 9   (100.0) 
NMW, n (%) 25   (75.8) 8   (24.2) 33   (100.0) 
NICU, n (%) 7   (70.0) 3   (30.0) 10   (100.0) 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 




Route of antimicrobial administration 
A total of 198 (39.1%) of 506 prescriptions were administered by the oral route, and 308 
(60.9%) by the parenteral route. The proportion of antimicrobials administered by the 
oral route ranged from 1 (3.7%) of 27 antimicrobial prescriptions in the PICUs to 69 
(51.9%) of 133 antimicrobial prescriptions in the PMWs (Table 3.10). 
 
Table 3.10. Route of administration of antimicrobials by department type, Global 
Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 
Yangon Children's Hospital, Yangon, Myanmar, December 2019 (N = 506) 
Department type 
Route of administration 
All prescriptions 
Oral route Parenteral route 
All wards 198  (39.1) 308  (60.9) 506 (100.0) 
PMW, n (%) 69  (51.9) 64  (48.1) 133 (100.0) 
PMW-HO, n (%) 17  (34.0) 33  (66.0) 50 (100.0) 
PSW, n (%) 101  (40.7) 147  (59.3) 248 (100.0) 
PICU, n (%) 1    (3.7) 26  (96.3) 27 (100.0) 
NWM, n (%) 9  (25.7) 26  (74.3) 35 (100.0) 
NICU, n (%) 1    (7.7) 12  (92.3) 13 (100.0) 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 




Reason for antimicrobial use in medical record 
A reason for antimicrobial use was recorded in the medical record for 286 (56.5%) of 
506 prescriptions. By ward, the recording of a reason for antimicrobial use in the medical 
record ranged from 20 (40.0%) of 50 antimicrobial prescriptions in the PMW-HO and 11 
(40.7%) of 27 antimicrobial prescriptions in the PICU, to 35 (100.0%) of 35 prescriptions 
and 13 (100.0%) of 13 prescriptions in the NMW and NICU, respectively (Table 3.11). 
 
Table 3.11. Reason for antimicrobial use in medical record by department type, 
Global Point-Prevalence Survey of Antimicrobial Consumption and Resistance at 
Yangon Children's Hospital, Yangon, Myanmar, December 2019 (N = 506) 
Department type 
Reason in medical record 
All prescriptions 
Yes No 
All wards 286   (56.5) 220 (43.5) 506 (100.0) 
PMW, n (%) 95   (71.4) 38  (28.6) 133 (100.0) 
PMW-HO, n (%) 20   (40.0) 30  (60.0) 50 (100.0) 
PSW, n (%) 112   (45.2) 136  (54.8) 248 (100.0) 
PICU, n (%) 11   (40.7) 16  (59.3) 27 (100.0) 
NWM, n (%) 35 (100.0) 0    (0.0) 35 (100.0) 
NICU, n (%) 13 (100.0) 0    (0.0) 13 (100.0) 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 




Stop or review date for prescription recorded in medical record 
A stop or review date was recorded in the medical record for 121 (23.9%) of 506 
antimicrobial prescriptions. The proportion of antimicrobials for which a stop or review 
date was recorded in the medical record ranged from 2 (7.4%) of 27 antimicrobial 
prescriptions in the PICUs and 35 (100.0%) of 35, and 13 (100.0%) of 13 antimicrobial 
prescriptions in the NMW and NICU, respectively (Table 3.12). 
 
Table 3.12. Prescription stop or review date in medical record for antimicrobials 
by department type, Global Point-Prevalence Survey of Antimicrobial 
Consumption and Resistance at Yangon Children's Hospital, Yangon, Myanmar, 
December 2019 (N = 506) 
Department type 
Stop or review date in medical record 
All prescriptions 
Yes No 
All wards 121   (23.9) 385 (76.1) 506  (100.0) 
PMW, n (%) 32   (24.1) 101 (75.9) 133  (100.0) 
PMW-HO, n (%) 14   (28.0) 36 (72.0) 50  (100.0) 
PSW, n (%) 25   (10.1) 223 (89.9) 248  (100.0) 
PICU, n (%) 2     (7.4) 25 (92.6) 27  (100.0) 
NWM, n (%) 35 (100.0) 0   (0.0) 35  (100.0) 
NICU, n (%) 13 (100.0) 0   (0.0) 13  (100.0) 
PMW, Paediatric Medical Wards; PMW-HO, Paediatric Haematology-Oncology Ward; 
PSW, Paediatric Surgical Wards; PICU, Paediatric Intensive Care Units; NMW, 





3.4.1 Key findings 
To our knowledge, ours was the first study of antimicrobial prescribing at a children’s 
hospital in Myanmar. We found that approximately 60.0% of patients admitted to YCH 
were prescribed at least one antimicrobial; more than 70.0% of these patients received 
an antimicrobial prescription informed by a biomarker result and fewer than 5.0% 
received an antimicrobial prescription informed by a microbiology test result. More than 
60.0% of antimicrobials prescribed at YCH were antibacterials for systemic use. Third-
generation cephalosporins alone accounted for more than one third of all antimicrobial 
prescriptions and were the most prevalent antimicrobial class prescribed for both 
therapeutic use and prophylactic use. Antibacterials prescribed for therapeutic use were 
most commonly for CAIs and antibacterials prescribed for prophylactic use were most 
commonly for SP. The majority of SP was for a duration >1 day. The three most common 
diagnoses for which antibacterials were prescribed were gastrointestinal tract 
prophylaxis; skin, soft tissue, bone, or joint prophylaxis; and pneumonia.  
 
Guidelines were only available for the diagnoses corresponding with a little over half of 
antimicrobial prescriptions. Of these, approximately 80.0% were guideline compliant, 
with guideline compliance highest among PMWs and PSWs, and lowest in the PMW-
HO. Moreover, approximately 60.0% of antimicrobials were prescribed by the parenteral 
route; a reason for antimicrobial use was recorded in the medical record for 
approximately half of antimicrobial prescriptions; and a stop or review date was recorded 
for about a quarter of antimicrobial prescriptions. 
 
3.4.2 Comparison with other studies 
Antimicrobial prescriptions 
We found that approximately 60.0% of patients at YCH were prescribed at least one 
antimicrobial. This prevalence is lower than that observed in a 2013 one-year 
prospective study at a single tertiary hospital in India where approximately 80.0% of 
paediatric patients received at least one antimicrobial (40), and comparable to that 
observed in a 2016 PPS at six hospitals in India where 61.5% of paediatric patients were 
prescribed at least one antimicrobial (41). In contrast, the prevalence of antimicrobial 
prescribing at YCH was considerably higher than that in a 2012 PPS at six Australian 
children’s hospitals, and a 2011 PPS of paediatric patients at 17 tertiary hospitals across 
the United Kingdom (UK) where 46.0% and 43.0% of paediatric patients were prescribed 
at least one antimicrobial, respectively. The prevalence of antimicrobial prescribing 
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observed at YCH was also higher than the worldwide prevalence of the 2012 Worldwide 
Antibiotic Resistance and Prescribing in European Children (ARPEC) PPS, where 
36.7% of paediatric patients received at least one antimicrobial (42). The higher 
prevalence of antimicrobial prescribing observed at YCH and other hospitals in LMICs 
compared with high-income countries (HICs) may be due to a higher burden of infectious 
diseases, more severe illnesses, or less restrictive antimicrobial prescribing policies 
(43,44). 
 
We found that 100.0% of patients in the NMW and more than 80.0% of patients in the 
PSWs and PICUs were prescribed at least one antimicrobial. Fewer studies have 
reported on antimicrobial use in the NMW compared with other department types 
included in the Global-PPS. The prevalence of antimicrobial use that we observed at 
YCH was considerably higher than the 12.3% of patients admitted to NMWs across the 
hospitals included in the 2012 Worldwide ARPEC PPS (42), which did report data on 
antimicrobial use in the NMW. High antimicrobial prescribing in the PSW and PICUs was 
consistent with results from the 2012 Worldwide ARPEC PPS and the 2011 UK PPS 
(42,45). The high prevalence of antimicrobial prescribing in PSW is likely due to many 
patients at YCH receiving antimicrobial SP (40). The high prevalence of antimicrobial 
prescribing in PICUs at YCH was likely due to the severity of infections, early empiric 
antimicrobial prescribing, high use of medical interventions such as catheters, and the 
lack of susceptibility of pathogens frequently encountered in intensive care units (46). 
We observed only approximately 40.0% of patients in the PMW-HO and NICU were 
prescribed at least one antimicrobial. Our results contrast with most other studies the 
2013 Indian one-year prospective study and the 2011 UK PPS where PMW-HO and 
intensive care units were among the wards with the highest antimicrobial prescribing 
(40,45). It is possible that a different proportional mix of specialties at YCH compared 
with other surveyed hospitals is responsible for the observed differences in the patterns 
of antimicrobial prescribing. For example, at YCH, 12.4% and 2.0% of patients were 
admitted to the PMW-HO and NICU, respectively; this contrasts with the 2012 
Worldwide ARPEC PPS where 20.3% and 19.9% of patients were admitted to these 
same ward department types (42). 
 
Antibacterial prescriptions 
As observed across other PPS, antibacterials for systemic use were more commonly 
prescribed at YCH than other antimicrobials (40,42,47). In our study, third-generation 
cephalosporins were the most commonly prescribed antimicrobials overall, across all 
department types, and across all treatment categories. The frequent use of third-
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generation cephalosporins was similar to that observed in a 2013 prospective study in 
India and in the Asia region during the 2012 Worldwide ARPEC PPS, but contrasted 
with the use of narrow-spectrum penicillins and penicillin and enzyme inhibitor 
combinations observed in the 2012 Australian PPS (41,42,47). This finding concurs with 
the observation made by Klein and colleagues that between 2000 and 2015 the 
consumption of cephalosporins increased rapidly in LMICs while declining in HICs (48). 
This is a cause for concern as the use of broad-spectrum antimicrobials, particularly 
third-generation cephalosporins, is associated with an increased risk of AMR emergence 
(5). 
 
Antibacterials prescribed by treatment indication 
We observed that approximately equal proportions of antibacterials were prescribed for 
therapeutic use and prophylactic use at YCH. This differed from most other studies, in 
both LMICs and HICs, where therapeutic use exceeded prophylactic use (40,42,47). 
YCH also differed in that fewer antibacterials were prescribed for HAIs and more 
antimicrobials were prescribed for SP than in other settings (40,42,47). The fact that our 
findings differed from those observed in other settings may suggest that we 
underestimated the prevalence of HAIs, perhaps due to underreporting of HAIs by 
clinical staff, data collectors misclassifying infection types, or some true HAIs not being 
captured as they had not yet been identified at the time of the survey (49–52). It is also 
possible that other studies overestimated the prevalence of HAIs or that our results were 
not directly comparable to other studies that reported HAIs as they used different 
classification criteria (53). The majority of antimicrobials prescribed for SP at YCH were 
for a duration ≥1 day and fewer than 4.0% were a single dose. This suggests that 
antimicrobial use for SP does not follow international guidelines that recommend that a 
single dose be administered within the 24-hour preoperative period and ideally within 60 
minutes of incision (34–36). Despite being inconsistent with international guidelines, our 
finding of SP being given for a duration ≥1 day was consistent with results from other 
PPS in India and Australia, and the 2012 Worldwide ARPEC PPS (42,45,47). Medical 
prophylaxis was also relatively more common at YCH than was observed in other 
studies. Given the limited number of widely accepted uses of medical prophylaxis, a 
proportion of these prescriptions were likely inappropriate and as such represent a 
potential area for further education on antimicrobial prescribing (25). Prolonged and 
otherwise inappropriate prophylactic antibacterial use can lead to increased selection of 
resistant organisms, adverse drug reactions, treatment related illnesses (e.g., C. difficile 




Antibacterial prescriptions by diagnosis  
The most common diagnosis for which antimicrobials were prescribed at YCH was 
gastrointestinal tract prophylaxis, followed by the skin, soft tissue, bone, or joint 
prophylaxis; pneumonia; and neutropenic fever. This finding differed from that observed 
in studies from other secondary and tertiary children’s hospitals where infection of the 
lower respiratory tract was the most common diagnosis and the prescribing of 
antimicrobials for skin and soft tissue, bone, or joint infection prophylaxis was 
uncommon (40,42,45,47). Consistent with other studies, we found that at YCH all forms 
of SP combined were a leading indication for antimicrobial prescription (42,47). The 
higher proportion of antimicrobials prescribed to prevent or treat infections of the 
gastrointestinal tract and the skin, soft tissue, bone, or joint, is likely due to the high 
proportion of patients in our sample admitted to a PSW, and reflects a different patient 
mix than reported elsewhere. At YCH 42.0% of patients were admitted to a PSW 
compared with 24.4% of patients from 44 secondary and 17 tertiary hospitals in the UK, 
and 12.8% of patients from 22 primary hospitals, 81 secondary hospitals, and 123 
tertiary hospitals in the Worldwide ARPEC PPS (42,45). 
 
Guideline compliance 
Local antimicrobial treatment guidelines were available for only 279 (55.1%) of 506 
antimicrobial prescriptions that we reviewed. There were few guidelines that explicitly 
called for antimicrobial prophylaxis, and there were limited guidelines for surgical 
conditions. Of the prescriptions with guidelines available, guideline compliance was 
highest on the PMW (88.3%), PSW (80.4%), and NMW (75.8%). Since almost half of 
antimicrobial prescriptions, particularly antimicrobials prescribed on the PSWs, PICUs 
and NICU, could not be assessed for guideline compliance it would be improper to 
compare guideline compliance observed in this study with guideline compliance 
observed in others. Furthermore, we did not collect data on why guidelines were not 
followed when a guideline was available. There are many possible barriers to guidelines 
not being followed, including guidelines not being available on the wards or being difficult 
to read and apply, treatments recommended by the guidelines not being available, 
clinicians not agreeing with the guideline recommendations, or clinicians not having the 
clinical knowledge or confidence necessary to follow the guideline (55,56). Ideally, 
guidelines should be developed using the best available evidence from the international 
literature adapted to reflect the specific patient needs, available healthcare resources, 
and training of clinicians in the local Myanmar context (55,57). Adapting guidelines to 




Route of administration 
We observed that more than 60.0% of antimicrobials were administered by the 
parenteral route. This finding was lower than that observed in the 2013 prospective study 
in India but comparable to that found in the 2011 UK PPS (40,45). This likely reflects the 
high use of third-generation cephalosporins, such as ceftriaxone and cefotaxime, and 
other parenteral antimicrobials at YCH for which no equivalent oral formulations are 
currently available (42). This may also reflect a belief among clinicians and patients that 
parenteral antimicrobials are superior and more effective than oral antimicrobials, and 
that de-escalation of antimicrobial administration from the parenteral route to the oral 
route is not given sufficient attention by clinicians (42,60). Consequently, the institution 
and enforcement of antimicrobial prescribing policies, including de-escalation of route of 
administration, could improve antimicrobial prescribing practices with regard to the 
current high use of parenteral antimicrobials. 
 
Documentation of antimicrobial prescriptions 
Documentation of antimicrobial prescriptions is important for ensuring transparency and 
allowing antimicrobial prescriptions to be reviewed and revised to optimise effectiveness 
and patient safety. A focus on starting, but not on reviewing or stopping, treatment can 
lead to unnecessary and prolonged duration of antimicrobial use (57). We observed that 
a reason for antimicrobial use recorded in the medical record for a little over half of 
antimicrobial prescriptions, and a stop or review date for approximately one-quarter of 
antimicrobial prescriptions at YCH. A reason for antimicrobial use being recorded in the 
medical record was lower than observed overall in the 2012 Worldwide ARPEC study 
but comparable to that observed in the Latin America region (42). No other studies of 
antimicrobial prescribing in paediatric patients found in the literature reported the 
prevalence of a stop or review date being recorded. However, the prevalence of a stop 
or review date being recorded at YCH was comparable to a multicentre PPS of all public, 
private and charity hospitals that treat paediatric and adult patients in Punjab, Pakistan 
(61). These findings suggest that greater attention being placed on the documentation 
of antimicrobial prescribing information, such as requiring a reason for antimicrobial use 
be recorded before an antimicrobial is dispensed or encouraging staff to include a stop 
or review date for all antimicrobial prescriptions, could improve the safety and 




3.4.3 Study strengths 
The major strengths of our cross-sectional survey were its previous validation, simply 
structured protocol and data collection forms, and automated data validation processes 
that ensured that a minimum acceptable level of data consistency was reached. The use 
of a standardised protocol also meant that results from YCH could be compared with 
results done elsewhere using the same protocol, and that the method can be repeated 
in subsequent years to identify changes in practice. While labour intensive on the day of 
the survey, the data collection process was straightforward and feasible in a low-
resource setting. We were able to compare antimicrobial prescribing across specialties 
and identify areas of prescribing that do not meet AMS expectations. The large size of 
YCH with both neonatal and paediatric department types means that our survey 
provides insight into antimicrobial prescribing to children of all ages and across multiple 
specialties.  
 
3.4.4 Study limitations 
Our study had a number of limitations. First, we only collected antimicrobial prescribing 
data on each ward on a single day chosen to be convenient for the clinical staff and 
cannot be certain that the prescribing practices observed were representative of typical 
prescribing practices. Antimicrobial prescribing practices may differ from day-to-day for 
a myriad of reasons including the prevalence of particular infectious diseases differing 
by season or antimicrobial prescribing patterns reflecting the experience and mix of 
clinical staff on the ward at the time of the survey. Evidence shows that prescribing errors 
are more common among junior and less experienced clinicians (62). Also, this survey 
was only conducted in one hospital, and the antimicrobial prescribing practices observed 
may not be directly generalisable to other hospitals in Myanmar.  
 
Second, study team members had restricted access to the hospital wards. We could 
only survey a ward when convenient for the clinical staff which was often on a ward’s 
pre-admission or admission days; days when fewer patients than possible were 
admitted. Also, as foreign nationals, Prof Crump, Dr Marchello, and I were not permitted 
access to the hospital wards. This restriction created logistical challenges for 
implementing quality control measures during data collection. This may have negatively 
impacted the quality of data collection as it created time delays between data collection 
and the correction of errors found during data verification. As medical records are 
amended regularly, there was a greater likelihood of data not reflecting the true 
circumstances at 8:00AM on the day of the survey when data were collected from the 




Third, due to the simplicity of the protocol and data collection forms, we did not collect 
some potentially useful data for assessing hospital-based antimicrobial prescribing. For 
example, we did not measure the severity and acuity of infection, the duration of 
antimicrobial use other than for SP, or whether clinical staff were awaiting a microbiology 
test result at the time of the survey and if they subsequently adjusted the antimicrobial 
prescription based on the microbiology test result. We also did not collect information on 
why parenteral antimicrobials were preferred over oral formulations, nor did we capture 
whether antimicrobials were later switched to the oral route. Although data collectors 
had access to medical records, subtleties in discussion relating to treatment decisions 
were likely missed. 
 
Fourth, we could only assess guideline compliance for diagnoses that were explicitly 
included in the ‘Pediatric Management Guidelines’. Notably, guidelines were not 
available for all encountered diagnoses including common conditions such as bronchitis. 
There were also guidelines for only a limited number of surgical conditions and very few 
guidelines explicitly recommended that antimicrobials be prescribed for prophylactic 
use. Furthermore, some guidelines that recommended antimicrobial use did not identify 
which specific antimicrobials should be used meaning that guideline compliance could 
not be assessed.  
 
Fifth, it is possible some antimicrobial prescribing data were recorded incorrectly in the 
medical record or transcribed incorrectly by data collectors, the data entry team, or our 
colleagues at the Global-PPS Coordination Centre. Although data collection was 
conducted by trained data collectors using a standardised protocol, monitoring of data 
collection was restricted, and there may have been inconsistencies among data 
collectors. We noticed errors in the recording of diagnosis codes and treatment 
indication codes, and the assessment of guideline compliance that led to changes in 
data verification processes. It is possible that errors also occurred in the collection of 
other data that went unnoticed. These errors may have been exacerbated by the 
restrictions placed on ward access that affected our planned quality control processes. 
The online validation built into the Global-PPS online database proved to be very useful 
as it enforced verification, correction, and validation of data. 
 
Finally, social desirability bias was also possible in our study. Social desirability bias was 
possible because the purpose of our survey was clear, and members of our research 
team may have desired to present clinical practice in Myanmar in a favourable manner. 
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This may have been so, as the Myanmar culture places a high value on deference and 
courtesy to older, more senior colleagues (63). Further, social science researchers have 
suggested that collaborations between Myanmar researchers and researchers from 
outside of Myanmar may lead to social desirability bias due to a desire among Myanmar 
researchers to present clinical practice in Myanmar in a favourable manner to the 
international research community (64). We predict that any social desirability bias in our 
study would likely have led to an underestimation of unfavourable antimicrobial 
prescribing patterns and behaviours.   
 
3.4.5 Recommendations 
The WHO and others recommend that all hospitals implement an evidence-based AMS 
programme to limit the emergence and spread of AMR (8,57,65). It is recommended that 
AMS programmes be tailored to reflect the environments in which they will be 
implemented and be structured to make prudent antimicrobial prescribing easier (7). The 
barriers to prudent antimicrobial prescribing in LMICs are several including the lack of 
orientation and training, diagnostic infrastructure and expertise, and lack of knowledge 
of optimal antimicrobial prescribing (58). At the individual hospital level, knowledge 
about what antimicrobials are prescribed and by whom is necessary for planning and 
implementing an AMS programme that overcome these barriers (26,45). This PPS was 
the first step in auditing the antimicrobial use at YCH and allowed the identification of 
priorities for quality improvement. Based on our results, we make several 
recommendations for an AMS programme at YCH: 
 
Recommendation 1: Establish an AMS team with the support of administrators 
and clinical staff 
In existing AMS programmes, there is often a dedicated AMS team consisting of 
infectious disease specialists, other senior clinicians, pharmacists, infection control 
nurses, and microbiologists (19). An AMS team at YCH may use currently available 
human resources or consider hiring individuals to fill vacant specialties with relevant 
infection control and AMS responsibilities, if possible. This AMS team can supplement 
the functions of the hospital’s pre-existing infection control team (10,20). As well as the 
dedicated and appropriately resourced AMS team, the support of hospital 





Recommendation 2: Institute preauthorisation and prospective audit with 
feedback  
Closer scrutiny of antimicrobial prescribing at YCH, including where necessary 
restricting certain antimicrobials, and providing feedback to clinicians on how to improve 
antimicrobial prescribing may improve antimicrobial use. Few studies from LMICs have 
described and evaluated AMS interventions in low-resource settings (7). Evidence from 
HICs indicates that preauthorisation and prospective audit with feedback are the most 
effective AMS interventions targeted at antimicrobial prescribing in hospitals (66,67). 
Utilising preauthorisation of certain antimicrobials may help optimise initial antimicrobial 
prescribing choices (66,68). Utilising prospective audit with feedback may additionally 
help optimise continued antimicrobial use through systematically looking for 
opportunities to narrow the spectrum of antimicrobial activity or switch antimicrobials 
from the parenteral to the oral route (54,66). 
 
Recommendation 3: Provide antimicrobial prescribing education for clinicians 
Education on the benefits of appropriate antimicrobial use and risks associated with 
inappropriate antimicrobial use is important to ensure that AMS messages are shared 
widely and to allow clinical staff to ask questions about both current and optimal 
prescribing practices (20,57). Education is particularly important for reiterating AMS 
messages and multiple educational sessions are often necessary to sustain any 
improvements in antimicrobial prescribing especially where there is a high turnover of 
staff (57,69). However, education alone has been shown to have a negligible effect on 
prescribing practices and is most effective when accompanying other more targeted 
AMS interventions (69). 
 
Recommendation 4: Develop further antimicrobial prescribing guidelines 
We observed a number of conditions were missing from the Myanmar Pediatric Society’s 
‘Pediatric Management Guidelines’. We recommend that further evidence-based 
antimicrobial prescribing guidelines be developed to cover a wider range of conditions 
including antimicrobial use for surgical and medical prophylaxis, and to improve their 
ease of use. These guidelines will ideally be made available in a text-searchable 
electronic format and revised regularly based on the YCH antibiogram (58,70). The 
Myanmar Pediatric Society’s ‘Pediatric Management Guidelines’ used at YCH lack a 
consistent and clear structure with regards to antimicrobial prescribing 
recommendations and are not easily consulted on the wards because of their extensive 
size (55). Furthermore, the document contained treatment guidelines for conditions 
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corresponding to only half of the antimicrobials prescribed in our survey, contained 
imprecise guidelines for some included conditions (e.g., guidelines suggest that severe 
burns may be treated with ‘broad-spectrum antibiotics’), and contained no guidelines for 
surgical prophylaxis. Improving the specificity of guidelines and making them easier to 
use will allow greater consistency of patient care and may help to reduce the empiric 
prescribing of broad-spectrum antibacterials such as third-generation cephalosporins.  
 
Recommendation 5: Improve the documentation of antimicrobial prescribing 
Documenting of the reason for antimicrobial use in the medical record is important. This 
can be achieved through ongoing clinician education, incorporation of documentation 
requirements into antimicrobial ordering forms, and respected senior clinicians setting 
an example and expectation of complete antimicrobial prescribing documentation 
(54,70,71). Absent or unclear recording of the reason for antimicrobial use makes the 
monitoring and adjustment of antimicrobial prescriptions difficult for other health 
professionals (72). Such difficulty in monitoring and adjusting antimicrobial prescriptions 
can increase the likelihood of adverse drug events and the development of AMR through 
prolonging the duration for which initial empiric antimicrobials, notably broad-spectrum 
antibacterials, are used (20,54,73).  
 
Recommendation 6: Require that a stop or review date be recorded for all 
antimicrobial prescriptions 
Appropriate antimicrobial prescribing requires that prescriptions be reviewed on a 
regular basis to ensure that the selected antimicrobial and the route of administration 
are appropriate, and that antimicrobial use is stopped if no longer necessary (20,57). 
Routine ward rounds, ongoing nursing care, and microbiology test results can be utilised 
to monitor patients’ clinical progress to identify opportunities to narrow the spectrum of 
antimicrobial activity or switch antimicrobials from the parenteral to the oral route 
(57,74). Beyond initial empiric prescribing, we recommend, that the use of parenteral 
antimicrobials be reserved for patients who are severely unwell, unable to tolerate oral 
antimicrobials, where oral antimicrobials are not available, or would provide inadequate 
tissue concentrations (57).  
 
Recommendation 7: Reduce unnecessary use of parenteral antimicrobials for 
initial empiric treatment  
We recommend that treatment guidelines specify the choice of antimicrobials, dose, and 
route of administration for initial empiric treatment of common childhood illnesses (57). 
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As the use of parenteral antimicrobials increases the risk of HAIs at the site of 
catheterisation, we recommend that their use be restricted to instances where it is 
absolutely necessary (16,57). The high prevalence of parenteral antimicrobial use for 
initial empiric treatment at YCH indicates that some prescribing is inappropriate, and that 
a suitable oral antimicrobial may be available. 
 
Recommendation 8: Promote more prudent antimicrobial use for surgical 
prophylaxis 
We observed that most antimicrobials prescribed for SP at YCH were broad-spectrum 
antibacterials that were given for a duration ≥1 day. This is in contrast to several 
international guidelines that recommend that a single dose of a narrow-spectrum 
antibacterial be administered within the 24-hour preoperative period (56,75,76). 
Reducing the use of broad-spectrum antibacterials and the duration of antimicrobial use 
for SP will aid in reducing selective pressures for AMR.  
 
Recommendation 9: Increase the use of microbiology testing 
We recommend that, where possible, samples for microbiology testing be collected prior 
to administration of antimicrobials and that the results of microbiology tests be used to 
rationalise initial empiric antimicrobial prescribing (57). We further recommend that 
treatment guidelines be reviewed regularly in light of the most recent YCH clinical 
microbiology laboratory antibiogram, and efforts be made to avoid unnecessary 
prescriptions of broad-spectrum antibacterials, particularly of third-generation 
cephalosporins that are associated with increased risk of AMR emergence and spread 
(57). 
 
Recommendation 10: Repeat PPS of antimicrobial consumption and resistance 
Multiple PPS over time will make it possible to measure any seasonal changes in 
infectious disease prevalence and antimicrobial prescribing patterns and evaluate the 
implementation and success of the various AMS interventions proposed above (26,45). 
This will also help to achieve the Myanmar government’s recent dedication to ongoing 
surveillance in the National Action Plan on Prevention and Containment of AMR (10).  
 
3.4.6 Conclusion 
Antimicrobial prescribing is common among patients admitted to YCH, and 
documentation of many prescriptions is limited and sometimes inappropriate. We 
propose that an AMS programme be implemented at YCH. We recommend that YCH 
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institutes evidence-based interventions that use preauthorisation and prospective audit 
with feedback to review antimicrobial prescribing choices, as well as interventions that 
seek to convert prescriptions from the parenteral to the oral route, and that aim to reduce 
the duration of antimicrobial use for SP. We also recommend that antimicrobial 
prescribing guidelines should be updated to include a greater number of conditions, 
improve ease of use, and to reflect local antimicrobial susceptibility patterns. Instituting 
an AMS programme with these interventions could greatly improve the appropriateness 
of antimicrobial prescribing at YCH and contribute to slowing the emergence and spread 
of AMR. Data collected in this survey can be used to inform the implementation of these 
AMS interventions and can provide a baseline for a series of PPS to monitor 
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4. Thesis Conclusion 
Antimicrobial resistance (AMR) in Salmonella Typhi, the bacterium responsible of 
typhoid fever, is an important and growing problem initially in Asia and now spreading 
also in Africa. Our systematic review showed that resistance has emerged to each of 
the principal antibacterials used to treat typhoid over time. Multiple-drug resistant strains 
are established in both Asia and Africa, and extensively-resistant strains are now 
emerging in Asia. It is presumed that antimicrobial resistance in Salmonella Typhi, a 
human host-restricted pathogen, is driven predominantly by antibacterial use in humans. 
In a community survey conducted in Yangon Region, Myanmar, we found that 
antibacterial use was commonly reported by individuals with fever. We observed that 
fever was most common among infants and children <12 years of age and private 
primary care centres were the most commonly utilised healthcare providers and the 
main source of antibacterials. Meanwhile, at Yangon Children’s Hospital, the largest 
paediatric referral hospital in Myanmar and a major provider of paediatric healthcare in 
Yangon, we found that the use of antibacterials and other antimicrobials is common. Of 
concern, third-generation cephalosporins and other broad spectrum antibacterials were 
widely used and surgical prophylaxis with antimicrobials was often prolonged.  
 
My research indicates that AMR should be considered in country-level decisions on 
whether or not to expand typhoid control measures, including the decision whether or 
not to introduce typhoid conjugate vaccines into routine immunisation schedules. 
Furthermore, my research shows that the use of antibacterials and other antimicrobials 
is widespread in both the community and hospital settings in the Yangon Region, and 
some of this use is likely inappropriate. Efforts to improve antimicrobial stewardship in 
Yangon Region are necessary to slow the emergence and spread of AMR. Since private 
primary care providers are a major source of antibacterials in the community in Yangon, 
their practices must be addressed in efforts to contain AMR. Antimicrobial stewardship 
in the community should seek to restrict access to antibacterials over-the-counter 
without a prescription and invest in infrastructure, staffing, and other resources 
necessary to correctly diagnose and treat infectious diseases. Strengthening of 
antimicrobial stewardship programmes in the hospital setting is also indicated. My 
research identified a number of potential AMS interventions to be applied at Yangon 
Children’s Hospital, notably: establishing a dedicated AMS team, developing further 
antimicrobial prescribing guidelines, and promoting more prudent antimicrobial use for 
surgical prophylaxis.   
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